,Drug,Recommendation,Rationale,Standardized,ExStandardized,Creatinine Clearance,Condition
0,Brompheniramine,Avoid,"Highly anticholinergic; clearance reduced with advanced age, and tolerance develops when used as hypnotic; risk of confusion, dry mouth, constipation, and other anticholinergic effects or toxicity","[""DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE"", ""BROMPHENIRAMINE MALEATE"", ""BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE"", ""BROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE"", ""DEXBROMPHENIRAMINE MALEATE"", ""DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE"", ""EFIDAC 24 PSEUDOEPHEDRINE HYDROCHLORIDE/BROMPHENIRAMINE MALEATE"", ""ACETAMINOPHEN; DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE"", ""BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE""]",BROMPHENIRAMINE,,
1,Carbinoxamine,Avoid,"Highly anticholinergic; clearance reduced with advanced age, and tolerance develops when used as hypnotic; risk of confusion, dry mouth, constipation, and other anticholinergic effects or toxicity","[""CARBINOXAMINE MALEATE""]",CARBINOXAMINE,,
2,Chlorpheniramine,Avoid,"Highly anticholinergic; clearance reduced with advanced age, and tolerance develops when used as hypnotic; risk of confusion, dry mouth, constipation, and other anticholinergic effects or toxicity","[""CHLORPHENIRAMINE MALEATE"", ""CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE"", ""CHLORPHENIRAMINE POLISTIREX; PHENYLPROPANOLAMINE POLISTIREX"", ""EFIDAC 24 CHLORPHENIRAMINE MALEATE"", ""HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX"", ""CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE"", ""HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE"", ""CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX"", ""CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE"", ""PSEUDOEPHEDRINE HYDROCHLORIDE AND CHLORPHENIRAMINE MALEATE"", ""CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE"", ""HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE"", ""DEXCHLORPHENIRAMINE MALEATE"", ""CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE"", ""CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX"", ""CHLORPHENIRAMINE MALEATE; IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE"", ""CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE"", ""CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE""]",CHLORPHENIRAMINE,,
3,Clemastine,Avoid,"Highly anticholinergic; clearance reduced with advanced age, and tolerance develops when used as hypnotic; risk of confusion, dry mouth, constipation, and other anticholinergic effects or toxicity","[""CLEMASTINE FUMARATE"", ""ACETAMINOPHEN; CLEMASTINE FUMARATE; PSEUDOEPHEDRINE HYDROCHLORIDE""]",CLEMASTINE,,
4,Cyproheptadine,Avoid,"Highly anticholinergic; clearance reduced with advanced age, and tolerance develops when used as hypnotic; risk of confusion, dry mouth, constipation, and other anticholinergic effects or toxicity","[""CYPROHEPTADINE HYDROCHLORIDE""]",CYPROHEPTADINE,,
5,Dexbrompheniramine,Avoid,"Highly anticholinergic; clearance reduced with advanced age, and tolerance develops when used as hypnotic; risk of confusion, dry mouth, constipation, and other anticholinergic effects or toxicity","[""ACETAMINOPHEN; DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE"", ""DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE"", ""DEXBROMPHENIRAMINE MALEATE"", ""DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE""]",DEXBROMPHENIRAMINE,,
6,Dexchlorpheniramine,Avoid,"Highly anticholinergic; clearance reduced with advanced age, and tolerance develops when used as hypnotic; risk of confusion, dry mouth, constipation, and other anticholinergic effects or toxicity","[""DEXCHLORPHENIRAMINE MALEATE""]",CHLORPHENIRAMINE,,
7,Dimenhydrinate,Avoid,"Highly anticholinergic; clearance reduced with advanced age, and tolerance develops when used as hypnotic; risk of confusion, dry mouth, constipation, and other anticholinergic effects or toxicity","[""DIMENHYDRINATE""]",DIMENHYDRINATE,,
8,Diphenhydramine (oral),Avoid. Use of diphenhydramine in situations such as acute treatment of severe allergic reaction may be appropriate,"Highly anticholinergic; clearance reduced with advanced age, and tolerance develops when used as hypnotic; risk of confusion, dry mouth, constipation, and other anticholinergic effects or toxicity",[],DIPHENHYDRAMINE,,
9,Doxylamine,Avoid,"Highly anticholinergic; clearance reduced with advanced age, and tolerance develops when used as hypnotic; risk of confusion, dry mouth, constipation, and other anticholinergic effects or toxicity","[""DOXYLAMINE SUCCINATE"", ""DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE"", ""DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE""]",DOXYLAMINE,,
10,Hydroxyzine,Avoid,"Highly anticholinergic; clearance reduced with advanced age, and tolerance develops when used as hypnotic; risk of confusion, dry mouth, constipation, and other anticholinergic effects or toxicity","[""HYDROXYZINE"", ""HYDROXYZINE HYDROCHLORIDE"", ""HYDROXYZINE PAMOATE""]",HYDROXYZINE,,
11,Meclizine,Avoid,"Highly anticholinergic; clearance reduced with advanced age, and tolerance develops when used as hypnotic; risk of confusion, dry mouth, constipation, and other anticholinergic effects or toxicity","[""MECLIZINE HYDROCHLORIDE""]",MECLIZINE,,
12,Promethazine,Avoid,"Highly anticholinergic; clearance reduced with advanced age, and tolerance develops when used as hypnotic; risk of confusion, dry mouth, constipation, and other anticholinergic effects or toxicity","[""PROMETHAZINE HYDROCHLORIDE"", ""PROMETHAZINE VC PLAIN"", ""PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE"", ""CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE"", ""PROMETHAZINE WITH CODEINE"", ""PROMETHAZINE HYDROCHLORIDE PLAIN"", ""PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE"", ""DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE"", ""MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE"", ""PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE"", ""PROMETHAZINE HYDROCHLORIDE; CODEINE PHOSPHATE"", ""PROMETHAZINE DM"", ""PROMETHAZINE HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE"", ""PROMETHAZINE W/ DEXTROMETHORPHAN"", ""PROMETHAZINE HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE"", ""PROMETHAZINE"", ""PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE"", ""PROMETHAZINE PLAIN"", ""PROMETHAZINE VC W/ CODEINE"", ""PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE"", ""CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE"", ""PROMETHAZINE W/ CODEINE"", ""PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE""]",PROMETHAZINE,,
13,Pyrilamine,Avoid,"Highly anticholinergic; clearance reduced with advanced age, and tolerance develops when used as hypnotic; risk of confusion, dry mouth, constipation, and other anticholinergic effects or toxicity","[""PHENYLEPHRINE HYDROCHLORIDE; PYRILAMINE MALEATE"", ""PYRILAMINE MALEATE""]",MEPYRAMINE,,
14,Triprolidine,Avoid,"Highly anticholinergic; clearance reduced with advanced age, and tolerance develops when used as hypnotic; risk of confusion, dry mouth, constipation, and other anticholinergic effects or toxicity","[""PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE"", ""CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE"", ""TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES"", ""TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES W/ CODEINE"", ""TRIPROLIDINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE"", ""TRIPROLIDINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE AND CODEINE PHOSPHATE"", ""TRIPROLIDINE HYDROCHLORIDE"", ""PSEUDOEPHEDRINE HYDROCHLORIDE AND TRIPROLIDINE HYDROCHLORIDE"", ""TRIPROLIDINE AND PSEUDOEPHEDRINE""]",TRIPROLIDINE,,
15,Benztropine (oral),Avoid,Not recommended for prevention or treatment of extrapyramidal symptoms with antipsychotics; more effective agents available for treatment of Parkinson disease,[],BENZATROPINE,,
16,Trihexyphenidyl,Avoid,Not recommended for prevention or treatment of extrapyramidal symptoms with antipsychotics; more effective agents available for treatment of Parkinson disease,"[""TRIHEXYPHENIDYL HYDROCHLORIDE""]",TRIHEXYPHENIDYL,,
17,Atropine (excludes ophthalmic),Avoid,"Highly anticholinergic, uncertain effectivenes",[],ATROPINE,,
18,Belladonna alkaloids,Avoid,"Highly anticholinergic, uncertain effectivenes",[],,,
19,Ipratropium,Avoid,"Highly anticholinergic, uncertain effectivenes","[""IPRATROPIUM BROMIDE"", ""ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE"", ""ALBUTEROL SULFATE; IPRATROPIUM BROMIDE""]",IPRATROPIUM BROMIDE,,
20,Hyoscyamine,Avoid,"Highly anticholinergic, uncertain effectivenes",[],HYOSCYAMINE,,
21,Scopolamine,Avoid,"Highly anticholinergic, uncertain effectivenes","[""METHSCOPOLAMINE BROMIDE"", ""SCOPOLAMINE""]",SCOPOLAMINE,,
22,Hyoscine,Avoid,"Highly anticholinergic, uncertain effectivenes",[],SCOPOLAMINE,,
23,Fentonium,Avoid,"Highly anticholinergic, uncertain effectivenes",[],PHENYTOIN,,
24,Methylatropine,Avoid,"Highly anticholinergic, uncertain effectivenes",[],METHOTREXATE,,
25,Butropium,Avoid,"Highly anticholinergic, uncertain effectivenes",[],,,
26,Clidinium-chlordiazepoxide,Avoid,"Highly anticholinergic, uncertain effectivenes",[],,,
27,Dicyclomine Homatropine (excludes opthalmic),Avoid,"Highly anticholinergic, uncertain effectivenes",[],DICYCLOMINE,,
28,Methscopolamine,Avoid,"Highly anticholinergic, uncertain effectivenes","[""METHSCOPOLAMINE BROMIDE""]",METHYLSCOPOLAMINE,,
29,Propantheline,Avoid,"Highly anticholinergic, uncertain effectivenes","[""PROPANTHELINE BROMIDE""]",PROPANTHELINE,,
30,"Dipyridamole, oral short acting",Avoid. Does not apply to the extended-release combination with aspirin,May cause orthostatic hypotension; more effective alternatives available; IV form acceptable for use in cardiac stress testing,[],DIPYRIDAMOLE,,
31,Nitrofurantoin ,Avoid if creatinine clearance <30mL/min or for long-term suppression,"Potential for pulmonary toxicity, hepatoxicity, and peripheral neuropathy, especially with long-term use; safer alternatives available","[""NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)"", ""NITROFURANTOIN SODIUM"", ""NITROFURANTOIN MACROCRYSTALLINE""]",NITROFURANTOIN,,
32,Doxazosin,Avoid if used to treat high blood pressure,"High risk of orthostatic hypotension and associated harms, especially in older adults; not recommended as routine treatment for hypertension; alternative agents have superior risk/benefit profile","[""DOXAZOSIN MESYLATE""]",DOXAZOSIN,,
33,Prazosin,Avoid if used to treat high blood pressure,"High risk of orthostatic hypotension and associated harms, especially in older adults; not recommended as routine treatment for hypertension; alternative agents have superior risk/benefit profile","[""PRAZOSIN HYDROCHLORIDE"", ""POLYTHIAZIDE; PRAZOSIN HYDROCHLORIDE""]",PRAZOSIN,,
34,Terazosin,Avoid if used to treat high blood pressure,"High risk of orthostatic hypotension and associated harms, especially in older adults; not recommended as routine treatment for hypertension; alternative agents have superior risk/benefit profile","[""TERAZOSIN HYDROCHLORIDE""]",TERAZOSIN,,
35,Clonidine,Avoid as a first-line treatment for high blood pressure,High risk of adverse CNS effects; may cause bradycardia and orthostatic hypotension; not recommended as routine treatment for hypertension,"[""CLONIDINE"", ""CLONIDINE HYDROCHLORIDE AND CHLORTHALIDONE"", ""CLONIDINE HYDROCHLORIDE "", ""CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE"", ""CLONIDINE HYDROCHLORIDE"", ""APRACLONIDINE HYDROCHLORIDE""]",CLONIDINE,,
36,Guanabenz,Avoid,High risk of adverse CNS effects; may cause bradycardia and orthostatic hypotension; not recommended as routine treatment for hypertension,"[""GUANABENZ ACETATE""]",,,
37,Guanfacine,Avoid,High risk of adverse CNS effects; may cause bradycardia and orthostatic hypotension; not recommended as routine treatment for hypertension,"[""GUANFACINE HYDROCHLORIDE""]",GUANFACINE,,
38,Methyldopa,Avoid,High risk of adverse CNS effects; may cause bradycardia and orthostatic hypotension; not recommended as routine treatment for hypertension,"[""HYDROCHLOROTHIAZIDE; METHYLDOPA"", ""METHYLDOPA AND CHLOROTHIAZIDE"", ""METHYLDOPA AND HYDROCHLOROTHIAZIDE"", ""METHYLDOPATE HYDROCHLORIDE"", ""METHYLDOPA"", ""CHLOROTHIAZIDE; METHYLDOPA"", ""METHYLDOPATE HCL""]",METHYLDOPA,,
39,Reserpine (>0.1 mg/day),Avoid,High risk of adverse CNS effects; may cause bradycardia and orthostatic hypotension; not recommended as routine treatment for hypertension,[],RESERPINE,,
40,Disopyramide,Avoid,May induce heart failure in older adults because of potent negative inotropic action; strongly anticholinergic; other antiarrhythmic drugs preferred,"[""DISOPYRAMIDE PHOSPHATE""]",DISOPYRAMIDE,,
41,Dronedarone,Avoid if diagnosed with atrial fibrillation or severe or recently decompensated heart failure,Worse outcomes have been reported in patients taking dronedarone who have permanent atrial fibrillation or severe or recently decompensated heart failure,"[""DRONEDARONE"", ""DRONEDARONE HYDROCHLORIDE""]",DRONEDARONE,,
42,Digoxin,"Avoid as a first-line treatment for atrial fibrillation or heart failure. If used as treatment for atrial fibrillation or heart failure, avoid dosages >0.125 mg/day","Use in atrial fibrillation: should not be used as a first-line agent in atrial fibrillation, because there are safer and more effective alternatives for rate control supported by
high-quality evidence
Use in heart failure: evidence for benefits and harms of digoxin is conflicting and of lower quality; most but not all of the evidence concerns use in HFrEF. There is strong evidence for other agents as first-line therapy to reduce hospitalizations and mortality in adults with HFrEF. In heart failure, higher dosages are not associated with additional benefit and may increase risk of toxicity. Decreased renal clearance of digoxin may lead to increased risk of toxic effects; further dose reduction may be necessary in those with stage 4 or 5 chronic kidney disease","[""DIGOXIN PEDIATRIC"", ""DIGOXIN""]",DIGOXIN,,
43,Nifedipine (immediate release),Avoid,Potential for hypotension; risk of precipitating myocardial ischemia,[],NIFEDIPINE,,
44,Amiodarone,Avoid as first-line therapy for atrial fibrillation unless diagnosed with heart failure or substantial left ventricular hypertrophy,Effective for maintaining sinus rhythm but has greater toxicities than other antiarrhythmics used in atrial fibrillation; may be reasonable first-line therapy in patients with concomitant heart failure or substantial left ventricular hypertrophy if rhythm control is preferred over rate control,"[""AMIODARONE HYDROCHLORIDE""]",AMIODARONE,,
45,Amitriptyline,Avoid,"Highly anticholinergic, sedating, and cause orthostatic hypotension","[""PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE"", ""CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE"", ""AMITRIPTYLINE HYDROCHLORIDE"", ""AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE"", ""AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE""]",AMITRIPTYLINE,,
46,Amoxapine,Avoid,"Highly anticholinergic, sedating, and cause orthostatic hypotension","[""AMOXAPINE""]",AMOXAPINE,,
47,Clomipramine,Avoid,"Highly anticholinergic, sedating, and cause orthostatic hypotension","[""CLOMIPRAMINE HYDROCHLORIDE""]",CLOMIPRAMINE,,
48,Desipramine,Avoid,"Highly anticholinergic, sedating, and cause orthostatic hypotension","[""DESIPRAMINE HYDROCHLORIDE""]",DESIPRAMINE,,
49,Doxepin (>6 mg/day),Avoid,"Highly anticholinergic, sedating, and cause orthostatic hypotension; safety profile of low-dose doxepin (≤6 mg/day) comparable to that of placebo",[],DOXEPIN,,
50,Imipramine,Avoid,"Highly anticholinergic, sedating, and cause orthostatic hypotension","[""TRIMIPRAMINE MALEATE"", ""IMIPRAMINE PAMOATE"", ""IMIPRAMINE HYDROCHLORIDE""]",IMIPRAMINE,,
51,Nortriptyline,Avoid,"Highly anticholinergic, sedating, and cause orthostatic hypotension","[""NORTRIPTYLINE HYDROCHLORIDE""]",NORTRIPTYLINE,,
52,Paroxetine,Avoid,"Highly anticholinergic, sedating, and cause orthostatic hypotension","[""PAROXETINE HYDROCHLORIDE"", ""PAROXETINE"", ""PAROXETINE MESYLATE""]",PAROXETINE,,
53,Protriptyline,Avoid,"Highly anticholinergic, sedating, and cause orthostatic hypotension","[""PROTRIPTYLINE HYDROCHLORIDE""]",PROTRIPTYLINE,,
54,Trimipramine,Avoid,"Highly anticholinergic, sedating, and cause orthostatic hypotension","[""TRIMIPRAMINE MALEATE""]",TRIMIPRAMINE,,
55,Chlorpromazine,"Avoid unless used for schizophrenia, bipolar disorder, or as a short-term antiemetic during chemotherapy","Increased risk of cerebrovascular accident (stroke) and greater rate of cognitive decline and mortality in persons with dementia. Avoid antipsychotics for behavioral problems of dementia or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others","[""CHLORPROMAZINE HYDROCHLORIDE"", ""CHLORPROMAZINE"", ""CHLORPROMAZINE HYDROCHLORIDE INTENSOL""]",CHLORPROMAZINE,,
56,Droperidol,"Avoid unless used for schizophrenia, bipolar disorder, or as a short-term antiemetic during chemotherapy","Increased risk of cerebrovascular accident (stroke) and greater rate of cognitive decline and mortality in persons with dementia. Avoid antipsychotics for behavioral problems of dementia or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others","[""DROPERIDOL"", ""FENTANYL CITRATE AND DROPERIDOL"", ""DROPERIDOL; FENTANYL CITRATE""]",DROPERIDOL,,
57,Fluphenazine,"Avoid unless used for schizophrenia, bipolar disorder, or as a short-term antiemetic during chemotherapy","Increased risk of cerebrovascular accident (stroke) and greater rate of cognitive decline and mortality in persons with dementia. Avoid antipsychotics for behavioral problems of dementia or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others","[""FLUPHENAZINE ENANTHATE"", ""FLUPHENAZINE HYDROCHLORIDE"", ""FLUPHENAZINE HCL"", ""FLUPHENAZINE"", ""FLUPHENAZINE DECANOATE""]",FLUPHENAZINE,,
58,Haloperidol,"Avoid unless used for schizophrenia, bipolar disorder, or as a short-term antiemetic during chemotherapy","Increased risk of cerebrovascular accident (stroke) and greater rate of cognitive decline and mortality in persons with dementia. Avoid antipsychotics for behavioral problems of dementia or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others","[""HALOPERIDOL DECANOATE"", ""HALOPERIDOL INTENSOL"", ""HALOPERIDOL LACTATE"", ""HALOPERIDOL""]",HALOPERIDOL,,
59,Loxapine,"Avoid unless used for schizophrenia, bipolar disorder, or as a short-term antiemetic during chemotherapy","Increased risk of cerebrovascular accident (stroke) and greater rate of cognitive decline and mortality in persons with dementia. Avoid antipsychotics for behavioral problems of dementia or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others","[""LOXAPINE SUCCINATE"", ""LOXAPINE"", ""LOXAPINE HYDROCHLORIDE""]",LOXAPINE,,
60,Perphenazine,"Avoid unless used for schizophrenia, bipolar disorder, or as a short-term antiemetic during chemotherapy","Increased risk of cerebrovascular accident (stroke) and greater rate of cognitive decline and mortality in persons with dementia. Avoid antipsychotics for behavioral problems of dementia or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others","[""AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE"", ""PERPHENAZINE"", ""PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE""]",PERPHENAZINE,,
61,Pimozide,"Avoid unless used for schizophrenia, bipolar disorder, or as a short-term antiemetic during chemotherapy","Increased risk of cerebrovascular accident (stroke) and greater rate of cognitive decline and mortality in persons with dementia. Avoid antipsychotics for behavioral problems of dementia or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others","[""PIMOZIDE""]",PIMOZIDE,,
62,Prochlorperazine,"Avoid unless used for schizophrenia, bipolar disorder, or as a short-term antiemetic during chemotherapy","Increased risk of cerebrovascular accident (stroke) and greater rate of cognitive decline and mortality in persons with dementia. Avoid antipsychotics for behavioral problems of dementia or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others","[""PROCHLORPERAZINE EDISYLATE"", ""PROCHLORPERAZINE MALEATE"", ""PROCHLORPERAZINE""]",PROCHLORPERAZINE,,
63,Thioridazine,"Avoid unless used for schizophrenia, bipolar disorder, or as a short-term antiemetic during chemotherapy","Increased risk of cerebrovascular accident (stroke) and greater rate of cognitive decline and mortality in persons with dementia. Avoid antipsychotics for behavioral problems of dementia or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others","[""THIORIDAZINE"", ""THIORIDAZINE HYDROCHLORIDE"", ""THIORIDAZINE HYDROCHLORIDE INTENSOL""]",THIORIDAZINE,,
64,Thiothixene,"Avoid unless used for schizophrenia, bipolar disorder, or as a short-term antiemetic during chemotherapy","Increased risk of cerebrovascular accident (stroke) and greater rate of cognitive decline and mortality in persons with dementia. Avoid antipsychotics for behavioral problems of dementia or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others","[""THIOTHIXENE HYDROCHLORIDE INTENSOL"", ""THIOTHIXENE HYDROCHLORIDE"", ""THIOTHIXENE""]",THIOTHIXENE,,
65,Trifluoperazine,"Avoid unless used for schizophrenia, bipolar disorder, or as a short-term antiemetic during chemotherapy","Increased risk of cerebrovascular accident (stroke) and greater rate of cognitive decline and mortality in persons with dementia. Avoid antipsychotics for behavioral problems of dementia or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others","[""TRIFLUOPERAZINE HYDROCHLORIDE"", ""TRIFLUOPERAZINE HCL""]",TRIFLUOPERAZINE,,
66,Aripiprazole,"Avoid unless used for schizophrenia, bipolar disorder, or as a short-term antiemetic during chemotherapy","Increased risk of cerebrovascular accident (stroke) and greater rate of cognitive decline and mortality in persons with dementia. Avoid antipsychotics for behavioral problems of dementia or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others","[""ARIPIPRAZOLE"", ""ARIPIPRAZOLE LAUROXIL""]",ARIPIPRAZOLE,,
67,Asenapine,"Avoid unless used for schizophrenia, bipolar disorder, or as a short-term antiemetic during chemotherapy","Increased risk of cerebrovascular accident (stroke) and greater rate of cognitive decline and mortality in persons with dementia. Avoid antipsychotics for behavioral problems of dementia or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others","[""ASENAPINE MALEATE"", ""ASENAPINE""]",ASENAPINE,,
68,Clozapine,"Avoid unless used for schizophrenia, bipolar disorder, or as a short-term antiemetic during chemotherapy","Increased risk of cerebrovascular accident (stroke) and greater rate of cognitive decline and mortality in persons with dementia. Avoid antipsychotics for behavioral problems of dementia or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others","[""CLOZAPINE""]",CLOZAPINE,,
69,Iloperidone,"Avoid unless used for schizophrenia, bipolar disorder, or as a short-term antiemetic during chemotherapy","Increased risk of cerebrovascular accident (stroke) and greater rate of cognitive decline and mortality in persons with dementia. Avoid antipsychotics for behavioral problems of dementia or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others","[""ILOPERIDONE""]",ILOPERIDONE,,
70,Lurasidone,"Avoid unless used for schizophrenia, bipolar disorder, or as a short-term antiemetic during chemotherapy","Increased risk of cerebrovascular accident (stroke) and greater rate of cognitive decline and mortality in persons with dementia. Avoid antipsychotics for behavioral problems of dementia or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others","[""LURASIDONE HYDROCHLORIDE""]",LURASIDONE,,
71,Olanzapine,"Avoid unless used for schizophrenia, bipolar disorder, or as a short-term antiemetic during chemotherapy","Increased risk of cerebrovascular accident (stroke) and greater rate of cognitive decline and mortality in persons with dementia. Avoid antipsychotics for behavioral problems of dementia or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others","[""FLUOXETINE HYDROCHLORIDE; OLANZAPINE"", ""OLANZAPINE"", ""OLANZAPINE PAMOATE"", ""OLANZAPINE AND FLUOXETINE HYDROCHLORIDE"", ""OLANZAPINE; SAMIDORPHAN L-MALATE""]",OLANZAPINE,,
72,Paliperidone,"Avoid unless used for schizophrenia, bipolar disorder, or as a short-term antiemetic during chemotherapy","Increased risk of cerebrovascular accident (stroke) and greater rate of cognitive decline and mortality in persons with dementia. Avoid antipsychotics for behavioral problems of dementia or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others","[""PALIPERIDONE"", ""PALIPERIDONE PALMITATE""]",PALIPERIDONE,,
73,Quetiapine,"Avoid unless used for schizophrenia, bipolar disorder, or as a short-term antiemetic during chemotherapy","Increased risk of cerebrovascular accident (stroke) and greater rate of cognitive decline and mortality in persons with dementia. Avoid antipsychotics for behavioral problems of dementia or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others","[""QUETIAPINE FUMARATE""]",QUETIAPINE,,
74,Risperidone,"Avoid unless used for schizophrenia, bipolar disorder, or as a short-term antiemetic during chemotherapy","Increased risk of cerebrovascular accident (stroke) and greater rate of cognitive decline and mortality in persons with dementia. Avoid antipsychotics for behavioral problems of dementia or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others","[""RISPERIDONE""]",RISPERIDONE,,
75,Ziprasidone,"Avoid unless used for schizophrenia, bipolar disorder, or as a short-term antiemetic during chemotherapy","Increased risk of cerebrovascular accident (stroke) and greater rate of cognitive decline and mortality in persons with dementia. Avoid antipsychotics for behavioral problems of dementia or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others","[""ZIPRASIDONE MESYLATE"", ""ZIPRASIDONE HYDROCHLORIDE""]",ZIPRASIDONE,,
76,Amobarbital,Avoid,"High rate of physical dependence, tolerance to sleep benefits, greater risk of overdose at low dosages",[],AMOBARBITAL,,
77,Butabarbital,Avoid,"High rate of physical dependence, tolerance to sleep benefits, greater risk of overdose at low dosages","[""BUTABARBITAL SODIUM"", ""SODIUM BUTABARBITAL"", ""BUTABARBITAL""]",,,
78,Butalbital,Avoid,"High rate of physical dependence, tolerance to sleep benefits, greater risk of overdose at low dosages","[""BUTALBITAL, ASPIRIN AND CAFFEINE"", ""BUTALBITAL; ACETAMINOPHEN; CAFFEINE; CODEINE PHOSPHATE"", ""BUTALBITAL; ACETAMINOPHEN; CAFFEINE; CODEINE"", ""ACETAMINOPHEN; BUTALBITAL"", ""BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE"", ""ASPIRIN; BUTALBITAL"", ""ASPIRIN; BUTALBITAL; CAFFEINE"", ""ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE"", ""BUTALBITAL, ACETAMINOPHEN AND CAFFEINE"", ""ACETAMINOPHEN; BUTALBITAL; CAFFEINE"", ""BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE"", ""BUTALBITAL AND ACETAMINOPHEN"", ""ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE""]",PHENYLBUTAZONE,,
79,Mephobarbital,Avoid,"High rate of physical dependence, tolerance to sleep benefits, greater risk of overdose at low dosages",[],METHYLPHENOBARBITAL,,
80,Pentobarbital,Avoid,"High rate of physical dependence, tolerance to sleep benefits, greater risk of overdose at low dosages","[""SODIUM PENTOBARBITAL"", ""PENTOBARBITAL SODIUM"", ""PENTOBARBITAL""]",PENTOBARBITAL,,
81,Phenobarbital,Avoid,"High rate of physical dependence, tolerance to sleep benefits, greater risk of overdose at low dosages",[],PHENOBARBITAL,,
82,Secobarbital,Avoid,"High rate of physical dependence, tolerance to sleep benefits, greater risk of overdose at low dosages","[""SECOBARBITAL SODIUM""]",SECOBARBITAL,,
83,Alprazolam,Avoid,"Older adults have increased sensitivity to benzodiazepines and decreased metabolism of long-acting agents; in general, all benzodiazepines increase risk of cognitive impairment, delirium, falls, fractures, and motor vehicle crashes in older adults
May be appropriate for seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine withdrawal, ethanol withdrawal, severe generalized anxiety disorder, and periprocedural anesthesia","[""ALPRAZOLAM""]",ALPRAZOLAM,,
84,Estazolam,Avoid,"Older adults have increased sensitivity to benzodiazepines and decreased metabolism of long-acting agents; in general, all benzodiazepines increase risk of cognitive impairment, delirium, falls, fractures, and motor vehicle crashes in older adults
May be appropriate for seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine withdrawal, ethanol withdrawal, severe generalized anxiety disorder, and periprocedural anesthesia","[""ESTAZOLAM""]",ESTAZOLAM,,
85,Lorazepam,Avoid,"Older adults have increased sensitivity to benzodiazepines and decreased metabolism of long-acting agents; in general, all benzodiazepines increase risk of cognitive impairment, delirium, falls, fractures, and motor vehicle crashes in older adults
May be appropriate for seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine withdrawal, ethanol withdrawal, severe generalized anxiety disorder, and periprocedural anesthesia","[""LORAZEPAM INTENSOL"", ""LORAZEPAM"", ""LORAZEPAM PRESERVATIVE FREE""]",LORAZEPAM,,
86,Oxazepam,Avoid,"Older adults have increased sensitivity to benzodiazepines and decreased metabolism of long-acting agents; in general, all benzodiazepines increase risk of cognitive impairment, delirium, falls, fractures, and motor vehicle crashes in older adults
May be appropriate for seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine withdrawal, ethanol withdrawal, severe generalized anxiety disorder, and periprocedural anesthesia","[""OXAZEPAM""]",OXAZEPAM,,
87,Temazepam,Avoid,"Older adults have increased sensitivity to benzodiazepines and decreased metabolism of long-acting agents; in general, all benzodiazepines increase risk of cognitive impairment, delirium, falls, fractures, and motor vehicle crashes in older adults
May be appropriate for seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine withdrawal, ethanol withdrawal, severe generalized anxiety disorder, and periprocedural anesthesia","[""TEMAZEPAM""]",TEMAZEPAM,,
88,Triazolam,Avoid,"Older adults have increased sensitivity to benzodiazepines and decreased metabolism of long-acting agents; in general, all benzodiazepines increase risk of cognitive impairment, delirium, falls, fractures, and motor vehicle crashes in older adults
May be appropriate for seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine withdrawal, ethanol withdrawal, severe generalized anxiety disorder, and periprocedural anesthesia","[""TRIAZOLAM""]",TRIAZOLAM,,
89,Chlordiazepoxide,Avoid,"Older adults have increased sensitivity to benzodiazepines and decreased metabolism of long-acting agents; in general, all benzodiazepines increase risk of cognitive impairment, delirium, falls, fractures, and motor vehicle crashes in older adults
May be appropriate for seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine withdrawal, ethanol withdrawal, severe generalized anxiety disorder, and periprocedural anesthesia","[""CHLORDIAZEPOXIDE HYDROCHLORIDE"", ""CHLORDIAZEPOXIDE"", ""CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE"", ""CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE"", ""CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE"", ""AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE"", ""CHLORDIAZEPOXIDE; ESTROGENS, ESTERIFIED""]",CHLORDIAZEPOXIDE,,
90,Clonazepam,Avoid,"Older adults have increased sensitivity to benzodiazepines and decreased metabolism of long-acting agents; in general, all benzodiazepines increase risk of cognitive impairment, delirium, falls, fractures, and motor vehicle crashes in older adults
May be appropriate for seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine withdrawal, ethanol withdrawal, severe generalized anxiety disorder, and periprocedural anesthesia","[""CLONAZEPAM""]",CLONAZEPAM,,
91,Clorazepate,Avoid,"Older adults have increased sensitivity to benzodiazepines and decreased metabolism of long-acting agents; in general, all benzodiazepines increase risk of cognitive impairment, delirium, falls, fractures, and motor vehicle crashes in older adults
May be appropriate for seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine withdrawal, ethanol withdrawal, severe generalized anxiety disorder, and periprocedural anesthesia","[""CLORAZEPATE DIPOTASSIUM""]",CLORAZEPATE,,
92,Diazepam,Avoid,"Older adults have increased sensitivity to benzodiazepines and decreased metabolism of long-acting agents; in general, all benzodiazepines increase risk of cognitive impairment, delirium, falls, fractures, and motor vehicle crashes in older adults
May be appropriate for seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine withdrawal, ethanol withdrawal, severe generalized anxiety disorder, and periprocedural anesthesia","[""DIAZEPAM INTENSOL"", ""DIAZEPAM""]",DIAZEPAM,,
93,Flurazepam,Avoid,"Older adults have increased sensitivity to benzodiazepines and decreased metabolism of long-acting agents; in general, all benzodiazepines increase risk of cognitive impairment, delirium, falls, fractures, and motor vehicle crashes in older adults
May be appropriate for seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine withdrawal, ethanol withdrawal, severe generalized anxiety disorder, and periprocedural anesthesia","[""FLURAZEPAM HYDROCHLORIDE""]",FLURAZEPAM,,
94,Quazepam,Avoid,"Older adults have increased sensitivity to benzodiazepines and decreased metabolism of long-acting agents; in general, all benzodiazepines increase risk of cognitive impairment, delirium, falls, fractures, and motor vehicle crashes in older adults
May be appropriate for seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine withdrawal, ethanol withdrawal, severe generalized anxiety disorder, and periprocedural anesthesia","[""QUAZEPAM""]",QUAZEPAM,,
95,Meprobamate,Avoid,High rate of physical dependence; sedating,"[""ASPIRIN; MEPROBAMATE"", ""MEPROBAMATE"", ""MEPROBAMATE AND ASPIRIN"", ""ESTROGENS, CONJUGATED; MEPROBAMATE""]",MEPROBAMATE,,
96,Bromazepam,Avoid,"Older adults have increased sensitivity to benzodiazepines and decreased metabolism of long-acting agents; in general, all benzodiazepines increase risk of cognitive impairment, delirium, falls, fractures, and motor vehicle crashes in older adults
May be appropriate for seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine withdrawal, ethanol withdrawal, severe generalized anxiety disorder, and periprocedural anesthesia",[],BROMAZEPAM,,
97,Clobazam,Avoid,"Older adults have increased sensitivity to benzodiazepines and decreased metabolism of long-acting agents; in general, all benzodiazepines increase risk of cognitive impairment, delirium, falls, fractures, and motor vehicle crashes in older adults
May be appropriate for seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine withdrawal, ethanol withdrawal, severe generalized anxiety disorder, and periprocedural anesthesia","[""CLOBAZAM""]",CLOBAZAM,,
98,Nitrazepam,Avoid,"Older adults have increased sensitivity to benzodiazepines and decreased metabolism of long-acting agents; in general, all benzodiazepines increase risk of cognitive impairment, delirium, falls, fractures, and motor vehicle crashes in older adults
May be appropriate for seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine withdrawal, ethanol withdrawal, severe generalized anxiety disorder, and periprocedural anesthesia",[],NITRAZEPAM,,
99,Clonazepam,Avoid,"Older adults have increased sensitivity to benzodiazepines and decreased metabolism of long-acting agents; in general, all benzodiazepines increase risk of cognitive impairment, delirium, falls, fractures, and motor vehicle crashes in older adults
May be appropriate for seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine withdrawal, ethanol withdrawal, severe generalized anxiety disorder, and periprocedural anesthesia","[""CLONAZEPAM""]",CLONAZEPAM,,
100,Eszopiclone,Avoid,"Nonbenzodiazepine benzodiazepine receptor agonist hypnotics have adverse events similar to those of benzodiazepines in older adults (eg, delirium, falls, fractures); increased emergency room visits/hospitalizations; motor vehicle crashes; minimal improvement in sleep latency and duration","[""ESZOPICLONE""]",ESZOPICLONE,,
101,Zaleplon,Avoid,"Nonbenzodiazepine benzodiazepine receptor agonist hypnotics have adverse events similar to those of benzodiazepines in older adults (eg, delirium, falls, fractures); increased emergency room visits/hospitalizations; motor vehicle crashes; minimal improvement in sleep latency and duration","[""ZALEPLON""]",ZALEPLON,,
102,Zolpidem,Avoid,"Nonbenzodiazepine benzodiazepine receptor agonist hypnotics have adverse events similar to those of benzodiazepines in older adults (eg, delirium, falls, fractures); increased emergency room visits/hospitalizations; motor vehicle crashes; minimal improvement in sleep latency and duration","[""ZOLPIDEM TARTRATE""]",ZOLPIDEM,,
103,Ergoloid mesylates,Avoid,Lack of efficacy,"[""ERGOLOID MESYLATES""]",ERGOLOID MESYLATE,,
104,Isoxsuprine,Avoid,Lack of efficacy,[],,,
105,Methyltestosterone,Avoid unless diagnosed with hypogonadism with clinical symptoms,Potential for cardiac problems; contraindicated in men with prostate cancer,"[""METHYLTESTOSTERONE""]",METHYLTESTOSTERONE,,
106,Testosterone,Avoid unless diagnosed with hypogonadism with clinical symptoms,Potential for cardiac problems; contraindicated in men with prostate cancer,"[""METHYLTESTOSTERONE"", ""TESTOSTERONE CYPIONATE"", ""TESTOSTERONE UNDECANOATE"", ""DEPO-TESTOSTERONE"", ""ESTRADIOL VALERATE; TESTOSTERONE ENANTHATE"", ""ESTRADIOL CYPIONATE; TESTOSTERONE CYPIONATE"", ""TESTOSTERONE ENANTHATE"", ""TESTOSTERONE"", ""TESTOSTERONE PROPIONATE"", ""TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE"", ""TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE""]",TESTOSTERONE,,
107,Desiccated thyroid ,Avoid,Concerns about cardiac effects; safer alternatives available,[],,,
108,Estradiol/Levonorgestrel,Avoid,"Evidence of carcinogenic potential (breast and endometrium); lack of cardioprotective effect and cognitive protection in older women.
Evidence indicates that vaginal estrogens for the treatment of vaginal dryness are safe and effective; women with a history of breast cancer who do not respond to nonhormonal therapies are advised to discuss the risks and benefits of low-dose vaginal estrogen (dosages of estradiol <25 μg twice weekly) with their healthcare provider",[],ESTRADIOL,,
109,Estradiol/Northindrone Acetate,Avoid,"Evidence of carcinogenic potential (breast and endometrium); lack of cardioprotective effect and cognitive protection in older women.
Evidence indicates that vaginal estrogens for the treatment of vaginal dryness are safe and effective; women with a history of breast cancer who do not respond to nonhormonal therapies are advised to discuss the risks and benefits of low-dose vaginal estrogen (dosages of estradiol <25 μg twice weekly) with their healthcare provider",[],ESTRADIOL,,
110,Estradiol/ Drospirenone,Avoid,"Evidence of carcinogenic potential (breast and endometrium); lack of cardioprotective effect and cognitive protection in older women.
Evidence indicates that vaginal estrogens for the treatment of vaginal dryness are safe and effective; women with a history of breast cancer who do not respond to nonhormonal therapies are advised to discuss the risks and benefits of low-dose vaginal estrogen (dosages of estradiol <25 μg twice weekly) with their healthcare provider",[],ESTRADIOL,,
111,Ospemifene,Avoid,"Evidence of carcinogenic potential (breast and endometrium); lack of cardioprotective effect and cognitive protection in older women.
Evidence indicates that vaginal estrogens for the treatment of vaginal dryness are safe and effective; women with a history of breast cancer who do not respond to nonhormonal therapies are advised to discuss the risks and benefits of low-dose vaginal estrogen (dosages of estradiol <25 μg twice weekly) with their healthcare provider","[""OSPEMIFENE""]",OSPEMIFENE,,
112,Estradiol/Norgestimate,Avoid,"Evidence of carcinogenic potential (breast and endometrium); lack of cardioprotective effect and cognitive protection in older women.
Evidence indicates that vaginal estrogens for the treatment of vaginal dryness are safe and effective; women with a history of breast cancer who do not respond to nonhormonal therapies are advised to discuss the risks and benefits of low-dose vaginal estrogen (dosages of estradiol <25 μg twice weekly) with their healthcare provider",[],ESTRADIOL,,
113,Estrogen/Medroxyprogesterone,Avoid,"Evidence of carcinogenic potential (breast and endometrium); lack of cardioprotective effect and cognitive protection in older women.
Evidence indicates that vaginal estrogens for the treatment of vaginal dryness are safe and effective; women with a history of breast cancer who do not respond to nonhormonal therapies are advised to discuss the risks and benefits of low-dose vaginal estrogen (dosages of estradiol <25 μg twice weekly) with their healthcare provider",[],CONJUGATED ESTROGENS,,
114,Estropipate,Avoid unless using intravaginally,"Evidence of carcinogenic potential (breast and endometrium); lack of cardioprotective effect and cognitive protection in older women.
Evidence indicates that vaginal estrogens for the treatment of vaginal dryness are safe and effective; women with a history of breast cancer who do not respond to nonhormonal therapies are advised to discuss the risks and benefits of low-dose vaginal estrogen (dosages of estradiol <25 μg twice weekly) with their healthcare provider","[""ESTROPIPATE""]",ESTRONE,,
115,Estrogen,Avoid unless using intravaginally,"Evidence of carcinogenic potential (breast and endometrium); lack of cardioprotective effect and cognitive protection in older women.
Evidence indicates that vaginal estrogens for the treatment of vaginal dryness are safe and effective; women with a history of breast cancer who do not respond to nonhormonal therapies are advised to discuss the risks and benefits of low-dose vaginal estrogen (dosages of estradiol <25 μg twice weekly) with their healthcare provider","[""NATURAL ESTROGENIC SUBSTANCE-ESTRONE"", ""CONJUGATED ESTROGENS/MEDROXYPROGESTERONE ACETATE"", ""SYNTHETIC CONJUGATED ESTROGENS A"", ""ESTERIFIED ESTROGENS"", ""ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE"", ""AMNESTROGEN"", ""ESTROGENIC SUBSTANCE"", ""ESTROGENS, CONJUGATED"", ""ESTROGENS, CONJUGATED SYNTHETIC B"", ""ESTROGENS, CONJUGATED SYNTHETIC A"", ""BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED"", ""DELESTROGEN"", ""ESTROGENS, ESTERIFIED"", ""CHLORDIAZEPOXIDE; ESTROGENS, ESTERIFIED"", ""ESTROGENS, CONJUGATED; MEPROBAMATE""]",CONJUGATED ESTROGENS,,
116,Estradiol,Avoid unless using intravaginally,"Evidence of carcinogenic potential (breast and endometrium); lack of cardioprotective effect and cognitive protection in older women.
Evidence indicates that vaginal estrogens for the treatment of vaginal dryness are safe and effective; women with a history of breast cancer who do not respond to nonhormonal therapies are advised to discuss the risks and benefits of low-dose vaginal estrogen (dosages of estradiol <25 μg twice weekly) with their healthcare provider","[""ESTRADIOL; NORETHINDRONE ACETATE"", ""ESTRADIOL CYPIONATE; MEDROXYPROGESTERONE ACETATE"", ""NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)"", ""NORETHINDRONE ACETATE;ETHINYL ESTRADIOL;ETHINYL ESTRADIOL;FERROUS FUMARATE"", ""ETHINYL ESTRADIOL; NORETHINDRONE"", ""NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE"", ""ESTRADIOL AND NORGESTIMATE"", ""ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE"", ""DEPO-ESTRADIOL"", ""NORETHINDRONE; ETHINYL ESTRADIOL"", ""ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE; ELAGOLIX SODIUM"", ""ESTRADIOL ACETATE"", ""ESTRADIOL HEMIHYDRATE"", ""ETHINYL ESTRADIOL; NORELGESTROMIN"", ""ESTRADIOL"", ""FLUOROESTRADIOL F-18"", ""NORGESTIMATE; ETHINYL ESTRADIOL"", ""ESTRADIOL; NORGESTIMATE"", ""ESTRADIOL; LEVONORGESTREL"", ""ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE ACETATE"", ""DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM"", ""NORGESTREL AND ETHINYL ESTRADIOL"", ""ETHINYL ESTRADIOL AND NORELGESTROMIN"", ""ETHINYL ESTRADIOL; LEVONORGESTREL"", ""ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL"", ""ETHINYL ESTRADIOL; ETONOGESTREL"", ""ESTRADIOL CYPIONATE; TESTOSTERONE CYPIONATE"", ""NORGESTIMATE AND ETHINYL ESTRADIOL"", ""NORETHINDRONE ACETATE; ETHINYL ESTRADIOL; ETHINYL ESTRADIOL; FERROUS FUMARATE"", ""ETHINYL ESTRADIOL; SEGESTERONE ACETATE"", ""ESTRADIOL; PROGESTERONE"", ""ESTRADIOL VALERATE AND DIENOGEST"", ""DROSPIRENONE; ETHINYL ESTRADIOL"", ""ESTRADIOL VALERATE"", ""NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE"", ""NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)"", ""DIENOGEST; ESTRADIOL VALERATE"", ""NORETHINDRONE AND ETHINYL ESTRADIOL"", ""DESOGESTREL; ETHINYL ESTRADIOL"", ""ETHINYL ESTRADIOL AND LEVONORGESTREL"", ""POLYESTRADIOL PHOSPHATE"", ""ETHINYL ESTRADIOL"", ""LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL"", ""ETHINYL ESTRADIOL; NORGESTREL"", ""ETHINYL ESTRADIOL;NORETHINDRONE; FERROUS FUMARATE"", ""NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE"", ""DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM "", ""ETHINYL ESTRADIOL; NORETHINDRONE ACETATE"", ""DROSPIRENONE; ESTRADIOL"", ""LEVONORGESTREL AND ETHINYL ESTRADIOL"", ""TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE"", ""ETHINYL ESTRADIOL; NORGESTIMATE"", ""NORETHINDRONE ACETATE;ETHINYL ESTRADIOL;FERROUS FUMARATE"", ""NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL"", ""ETHINYL ESTRADIOL; LEVONORGESTREL; FERROUS FUMARATE"", ""ESTRADIOL CYPIONATE"", ""ESTRADIOL AND NORETHINDRONE ACETATE"", ""ESTRADIOL VALERATE; TESTOSTERONE ENANTHATE"", ""ESTRADIOL VALERATE; ESTRADIOL VALERATE; DIENOGEST"", ""ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE"", ""DESOGESTREL AND ETHINYL ESTRADIOL"", ""DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM"", ""ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX"", ""DROSPIRENONE AND ETHINYL ESTRADIOL"", ""TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE""]",ESTRADIOL,,
117,Growth Hormone,Avoid unless diagnosed with growth hormone deficiency due to established etiology,"Impact on body composition is small and associated with edema, arthralgia, carpal tunnel syndrome, gynecomastia, impaired fasting glucose",[],PEGVISOMANT,,
118,Insulin Lispro,Avoid unless using with concurrent long-acting insulin,"Higher risk of hypoglycemia without improvement in hyperglycemia management regardless of care setting
Avoid insulin regimens that include only short- or rapid-acting insulin dosed according to current blood glucose levels without concurrent use of basal or long-acting insulin. This recommendation does not apply to regimens that contain basal insulin or long-acting insulin","[""INSULIN LISPRO-AABC"", ""INSULIN LISPRO"", ""INSULIN LISPRO RECOMBINANT"", ""INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT""]",INSULIN LISPRO,,
119,Insulin,Avoid unless using with concurrent long-acting insulin,"Higher risk of hypoglycemia without improvement in hyperglycemia management regardless of care setting
Avoid insulin regimens that include only short- or rapid-acting insulin dosed according to current blood glucose levels without concurrent use of basal or long-acting insulin. This recommendation does not apply to regimens that contain basal insulin or long-acting insulin","[""INSULIN DETEMIR"", ""INSULIN DEGLUDEC"", ""INSULIN GLARGINE"", ""INSULIN HUMAN"", ""INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT"", ""INSULIN ZINC SUSP EXTENDED PURIFIED BEEF"", ""INSULIN ASPART"", ""INSULIN RECOMBINANT HUMAN"", ""INSULIN LISPRO-AABC"", ""INSULIN DETEMIR RECOMBINANT"", ""INSULIN GLARGINE; LIXISENATIDE"", ""INSULIN GLARGINE-AGLR"", ""INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN"", ""INSULIN SUSP ISOPHANE RECOMBINANT HUMAN"", ""INSULIN GLARGINE-YFGN"", ""INSULIN DEGLUDEC; LIRAGLUTIDE"", ""INSULIN ASPART RECOMBINANT"", ""INSULIN LISPRO"", ""INSULIN GLULISINE RECOMBINANT"", ""INSULIN GLARGINE RECOMBINANT"", ""INSULIN LISPRO RECOMBINANT"", ""INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT"", ""INSULIN ASPART; INSULIN DEGLUDEC""]",INSULIN ASPART,,
120,Insulin Aspart,Avoid unless using with concurrent long-acting insulin,"Higher risk of hypoglycemia without improvement in hyperglycemia management regardless of care setting
Avoid insulin regimens that include only short- or rapid-acting insulin dosed according to current blood glucose levels without concurrent use of basal or long-acting insulin. This recommendation does not apply to regimens that contain basal insulin or long-acting insulin","[""INSULIN ASPART; INSULIN DEGLUDEC"", ""INSULIN ASPART RECOMBINANT"", ""INSULIN ASPART"", ""INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT""]",INSULIN ASPART,,
121,Insulin Glulisine,Avoid unless using with concurrent long-acting insulin,"Higher risk of hypoglycemia without improvement in hyperglycemia management regardless of care setting
Avoid insulin regimens that include only short- or rapid-acting insulin dosed according to current blood glucose levels without concurrent use of basal or long-acting insulin. This recommendation does not apply to regimens that contain basal insulin or long-acting insulin","[""INSULIN GLULISINE RECOMBINANT""]",INSULIN GLULISINE,,
122,Megestrol ,Avoid,Minimal effect on weight; increases risk of thrombotic events and possibly death in older adults,"[""MEGESTROL ACETATE""]",MEGESTROL,,
123,Chlorpropamide,Avoid,Prolonged half-life in older adults; can cause prolonged hypoglycemia; causes SIADH,"[""CHLORPROPAMIDE""]",CHLORPROPAMIDE,,
124,Glimepiride,Avoid,Higher risk of severe prolonged hypoglycemia in older adults,"[""GLIMEPIRIDE; ROSIGLITAZONE MALEATE"", ""ROSIGLITAZONE MALEATE AND GLIMEPIRIDE"", ""PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE"", ""GLIMEPIRIDE"", ""GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE""]",GLIMEPIRIDE,,
125,Glibenclamide,Avoid,Higher risk of severe prolonged hypoglycemia in older adults,[],GLYBURIDE,,
126,Glyburide,Avoid,Higher risk of severe prolonged hypoglycemia in older adults,"[""GLYBURIDE (MICRONIZED)"", ""GLYBURIDE AND METFORMIN HYDROCHLORIDE"", ""GLYBURIDE"", ""GLYBURIDE; METFORMIN HYDROCHLORIDE""]",GLYBURIDE,,
127,Metoclopramide,Avoid unless used for gastroparesis (use not to exceed 12 weeks),"Can cause extrapyramidal effects, including tardive dyskinesia; risk may be greater in frail older adults and with prolonged exposure","[""METOCLOPRAMIDE"", ""METOCLOPRAMIDE HCL"", ""METOCLOPRAMIDE HYDROCHLORIDE"", ""METOCLOPRAMIDE INTENSOL""]",METOCLOPRAMIDE,,
128,Mineral oil (oral),Avoid,Potential for aspiration and adverse effects; safer alternatives available,[],,,
129,Omeprazole,"Avoid scheduled use for >8 weeks unless for high-risk patients (eg, oral corticosteroids or chronic NSAID use), erosive esophagitis, Barrett esophagitis, pathological hypersecretory condition, or demonstrated need for maintenance treatment (eg, because of failure of drug discontinuation trial or H2-receptor antagonists)",Risk of Clostridium difficile infection and bone loss and fractures,"[""ESOMEPRAZOLE SODIUM"", ""MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE"", ""ESOMEPRAZOLE MAGNESIUM"", ""OMEPRAZOLE; SODIUM BICARBONATE"", ""ASPIRIN; OMEPRAZOLE"", ""AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE"", ""ESOMEPRAZOLE STRONTIUM"", ""OMEPRAZOLE"", ""AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN"", ""OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN"", ""OMEPRAZOLE MAGNESIUM"", ""OMEPRAZOLE AND SODIUM BICARBONATE"", ""NAPROXEN AND ESOMEPRAZOLE MAGNESIUM"", ""ESOMEPRAZOLE MAGNESIUM; NAPROXEN"", ""MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE""]",OMEPRAZOLE,,
130,Lansoprazole,"Avoid scheduled use for >8 weeks unless for high-risk patients (eg, oral corticosteroids or chronic NSAID use), erosive esophagitis, Barrett esophagitis, pathological hypersecretory condition, or demonstrated need for maintenance treatment (eg, because of failure of drug discontinuation trial or H2-receptor antagonists)",Risk of Clostridium difficile infection and bone loss and fractures,"[""AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE"", ""LANSOPRAZOLE; NAPROXEN"", ""LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN (COPACKAGED)"", ""DEXLANSOPRAZOLE"", ""LANSOPRAZOLE""]",LANSOPRAZOLE,,
131,Pantoprazole,"Avoid scheduled use for >8 weeks unless for high-risk patients (eg, oral corticosteroids or chronic NSAID use), erosive esophagitis, Barrett esophagitis, pathological hypersecretory condition, or demonstrated need for maintenance treatment (eg, because of failure of drug discontinuation trial or H2-receptor antagonists)",Risk of Clostridium difficile infection and bone loss and fractures,"[""PANTOPRAZOLE SODIUM""]",PANTOPRAZOLE,,
132,Rabeprazole,"Avoid scheduled use for >8 weeks unless for high-risk patients (eg, oral corticosteroids or chronic NSAID use), erosive esophagitis, Barrett esophagitis, pathological hypersecretory condition, or demonstrated need for maintenance treatment (eg, because of failure of drug discontinuation trial or H2-receptor antagonists)",Risk of Clostridium difficile infection and bone loss and fractures,"[""RABEPRAZOLE SODIUM""]",RABEPRAZOLE,,
133,Esomeprazole,"Avoid scheduled use for >8 weeks unless for high-risk patients (eg, oral corticosteroids or chronic NSAID use), erosive esophagitis, Barrett esophagitis, pathological hypersecretory condition, or demonstrated need for maintenance treatment (eg, because of failure of drug discontinuation trial or H2-receptor antagonists)",Risk of Clostridium difficile infection and bone loss and fractures,"[""ESOMEPRAZOLE SODIUM"", ""ESOMEPRAZOLE MAGNESIUM"", ""ESOMEPRAZOLE STRONTIUM"", ""NAPROXEN AND ESOMEPRAZOLE MAGNESIUM"", ""ESOMEPRAZOLE MAGNESIUM; NAPROXEN""]",ESOMEPRAZOLE,,
134,Dexlansoprazole,"Avoid scheduled use for >8 weeks unless for high-risk patients (eg, oral corticosteroids or chronic NSAID use), erosive esophagitis, Barrett esophagitis, pathological hypersecretory condition, or demonstrated need for maintenance treatment (eg, because of failure of drug discontinuation trial or H2-receptor antagonists)",Risk of Clostridium difficile infection and bone loss and fractures,"[""DEXLANSOPRAZOLE""]",LANSOPRAZOLE,,
135,Meperidine,Avoid,"Oral analgesic not effective in dosages commonly used; may have higher risk of neurotoxicity, including delirium, than other opioids; safer alternatives available","[""MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE"", ""ATROPINE SULFATE; MEPERIDINE HYDROCHLORIDE"", ""MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE"", ""MEPERIDINE AND ATROPINE SULFATE"", ""MEPERIDINE HYDROCHLORIDE""]",MEPERIDINE,,
136,Aspirin (>325 mg/day),"Avoid chronic use, unless other alternatives are not effective and patient can take gastroprotective agent (proton-pump inhibitor or misoprostol)","Increased risk of gastrointestinal bleeding or peptic ulcer disease in high-risk groups, including those >75 years or taking oral or parenteral corticosteroids, anticoagulants, or antiplatelet agents; use of proton-pump inhibitor or misoprostol reduces but does not eliminate risk. Upper gastrointestinal ulcers, gross bleeding, or perforation caused by NSAIDs occur in ~1% of patients treated for 3-6 months and in ~2%-4% of patients treated for 1 year; these trends continue with longer duration of use. Also can increase blood pressure and induce kidney injury. Risks are dose related",[],ACETYLSALICYLIC ACID,,
137,Diclofenac,"Avoid chronic use, unless other alternatives are not effective and patient can take gastroprotective agent (proton-pump inhibitor or misoprostol)","Increased risk of gastrointestinal bleeding or peptic ulcer disease in high-risk groups, including those >75 years or taking oral or parenteral corticosteroids, anticoagulants, or antiplatelet agents; use of proton-pump inhibitor or misoprostol reduces but does not eliminate risk. Upper gastrointestinal ulcers, gross bleeding, or perforation caused by NSAIDs occur in ~1% of patients treated for 3-6 months and in ~2%-4% of patients treated for 1 year; these trends continue with longer duration of use. Also can increase blood pressure and induce kidney injury. Risks are dose related","[""DICLOFENAC POTASSIUM"", ""DICLOFENAC SODIUM; MISOPROSTOL"", ""DICLOFENAC SODIUM"", ""DICLOFENAC SODIUM "", ""DICLOFENAC"", ""DICLOFENAC SODIUM AND MISOPROSTOL"", ""DICLOFENAC EPOLAMINE""]",DICLOFENAC,,
138,Diflunisal,"Avoid chronic use, unless other alternatives are not effective and patient can take gastroprotective agent (proton-pump inhibitor or misoprostol)","Increased risk of gastrointestinal bleeding or peptic ulcer disease in high-risk groups, including those >75 years or taking oral or parenteral corticosteroids, anticoagulants, or antiplatelet agents; use of proton-pump inhibitor or misoprostol reduces but does not eliminate risk. Upper gastrointestinal ulcers, gross bleeding, or perforation caused by NSAIDs occur in ~1% of patients treated for 3-6 months and in ~2%-4% of patients treated for 1 year; these trends continue with longer duration of use. Also can increase blood pressure and induce kidney injury. Risks are dose related","[""DIFLUNISAL""]",DIFLUNISAL,,
139,Etodolac,"Avoid chronic use, unless other alternatives are not effective and patient can take gastroprotective agent (proton-pump inhibitor or misoprostol)","Increased risk of gastrointestinal bleeding or peptic ulcer disease in high-risk groups, including those >75 years or taking oral or parenteral corticosteroids, anticoagulants, or antiplatelet agents; use of proton-pump inhibitor or misoprostol reduces but does not eliminate risk. Upper gastrointestinal ulcers, gross bleeding, or perforation caused by NSAIDs occur in ~1% of patients treated for 3-6 months and in ~2%-4% of patients treated for 1 year; these trends continue with longer duration of use. Also can increase blood pressure and induce kidney injury. Risks are dose related","[""ETODOLAC""]",ETODOLAC,,
140,Fenoprofen,"Avoid chronic use, unless other alternatives are not effective and patient can take gastroprotective agent (proton-pump inhibitor or misoprostol)","Increased risk of gastrointestinal bleeding or peptic ulcer disease in high-risk groups, including those >75 years or taking oral or parenteral corticosteroids, anticoagulants, or antiplatelet agents; use of proton-pump inhibitor or misoprostol reduces but does not eliminate risk. Upper gastrointestinal ulcers, gross bleeding, or perforation caused by NSAIDs occur in ~1% of patients treated for 3-6 months and in ~2%-4% of patients treated for 1 year; these trends continue with longer duration of use. Also can increase blood pressure and induce kidney injury. Risks are dose related","[""FENOPROFEN CALCIUM""]",FENOPROFEN,,
141,Ibuprofen,"Avoid chronic use, unless other alternatives are not effective and patient can take gastroprotective agent (proton-pump inhibitor or misoprostol)","Increased risk of gastrointestinal bleeding or peptic ulcer disease in high-risk groups, including those >75 years or taking oral or parenteral corticosteroids, anticoagulants, or antiplatelet agents; use of proton-pump inhibitor or misoprostol reduces but does not eliminate risk. Upper gastrointestinal ulcers, gross bleeding, or perforation caused by NSAIDs occur in ~1% of patients treated for 3-6 months and in ~2%-4% of patients treated for 1 year; these trends continue with longer duration of use. Also can increase blood pressure and induce kidney injury. Risks are dose related","[""HYDROCODONE BITARTRATE; IBUPROFEN"", ""FAMOTIDINE; IBUPROFEN"", ""IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE"", ""CHILDREN'S IBUPROFEN"", ""IBUPROFEN LYSINE"", ""OXYCODONE HYDROCHLORIDE AND IBUPROFEN"", ""IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE"", ""IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE"", ""IBUPROFEN SODIUM"", ""HYDROCODONE BITARTRATE AND IBUPROFEN"", ""DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN"", ""CHLORPHENIRAMINE MALEATE; IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE"", ""IBUPROFEN AND DIPHENHYDRAMINE CITRATE"", ""IBUPROFEN; OXYCODONE HYDROCHLORIDE"", ""ACETAMINOPHEN; IBUPROFEN"", ""CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE"", ""IBUPROFEN"", ""IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE"", ""DIPHENHYDRAMINE CITRATE; IBUPROFEN"", ""IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE"", ""IBUPROFEN AND FAMOTIDINE"", ""JUNIOR STRENGTH IBUPROFEN""]",IBUPROFEN,,
142,Ketoprofen,"Avoid chronic use, unless other alternatives are not effective and patient can take gastroprotective agent (proton-pump inhibitor or misoprostol)","Increased risk of gastrointestinal bleeding or peptic ulcer disease in high-risk groups, including those >75 years or taking oral or parenteral corticosteroids, anticoagulants, or antiplatelet agents; use of proton-pump inhibitor or misoprostol reduces but does not eliminate risk. Upper gastrointestinal ulcers, gross bleeding, or perforation caused by NSAIDs occur in ~1% of patients treated for 3-6 months and in ~2%-4% of patients treated for 1 year; these trends continue with longer duration of use. Also can increase blood pressure and induce kidney injury. Risks are dose related","[""KETOPROFEN""]",KETOPROFEN,,
143,Meclofenamate,"Avoid chronic use, unless other alternatives are not effective and patient can take gastroprotective agent (proton-pump inhibitor or misoprostol)","Increased risk of gastrointestinal bleeding or peptic ulcer disease in high-risk groups, including those >75 years or taking oral or parenteral corticosteroids, anticoagulants, or antiplatelet agents; use of proton-pump inhibitor or misoprostol reduces but does not eliminate risk. Upper gastrointestinal ulcers, gross bleeding, or perforation caused by NSAIDs occur in ~1% of patients treated for 3-6 months and in ~2%-4% of patients treated for 1 year; these trends continue with longer duration of use. Also can increase blood pressure and induce kidney injury. Risks are dose related","[""MECLOFENAMATE SODIUM""]",MECLOFENAMIC ACID,,
144,Mefenamic Acid,"Avoid chronic use, unless other alternatives are not effective and patient can take gastroprotective agent (proton-pump inhibitor or misoprostol)","Increased risk of gastrointestinal bleeding or peptic ulcer disease in high-risk groups, including those >75 years or taking oral or parenteral corticosteroids, anticoagulants, or antiplatelet agents; use of proton-pump inhibitor or misoprostol reduces but does not eliminate risk. Upper gastrointestinal ulcers, gross bleeding, or perforation caused by NSAIDs occur in ~1% of patients treated for 3-6 months and in ~2%-4% of patients treated for 1 year; these trends continue with longer duration of use. Also can increase blood pressure and induce kidney injury. Risks are dose related","[""MEFENAMIC ACID""]",MEFENAMIC ACID,,
145,Meloxicam,"Avoid chronic use, unless other alternatives are not effective and patient can take gastroprotective agent (proton-pump inhibitor or misoprostol)","Increased risk of gastrointestinal bleeding or peptic ulcer disease in high-risk groups, including those >75 years or taking oral or parenteral corticosteroids, anticoagulants, or antiplatelet agents; use of proton-pump inhibitor or misoprostol reduces but does not eliminate risk. Upper gastrointestinal ulcers, gross bleeding, or perforation caused by NSAIDs occur in ~1% of patients treated for 3-6 months and in ~2%-4% of patients treated for 1 year; these trends continue with longer duration of use. Also can increase blood pressure and induce kidney injury. Risks are dose related","[""MELOXICAM"", ""BUPIVACAINE; MELOXICAM""]",MELOXICAM,,
146,Nabumetone,"Avoid chronic use, unless other alternatives are not effective and patient can take gastroprotective agent (proton-pump inhibitor or misoprostol)","Increased risk of gastrointestinal bleeding or peptic ulcer disease in high-risk groups, including those >75 years or taking oral or parenteral corticosteroids, anticoagulants, or antiplatelet agents; use of proton-pump inhibitor or misoprostol reduces but does not eliminate risk. Upper gastrointestinal ulcers, gross bleeding, or perforation caused by NSAIDs occur in ~1% of patients treated for 3-6 months and in ~2%-4% of patients treated for 1 year; these trends continue with longer duration of use. Also can increase blood pressure and induce kidney injury. Risks are dose related","[""NABUMETONE""]",NABUMETONE,,
147,Naproxen,"Avoid chronic use, unless other alternatives are not effective and patient can take gastroprotective agent (proton-pump inhibitor or misoprostol)","Increased risk of gastrointestinal bleeding or peptic ulcer disease in high-risk groups, including those >75 years or taking oral or parenteral corticosteroids, anticoagulants, or antiplatelet agents; use of proton-pump inhibitor or misoprostol reduces but does not eliminate risk. Upper gastrointestinal ulcers, gross bleeding, or perforation caused by NSAIDs occur in ~1% of patients treated for 3-6 months and in ~2%-4% of patients treated for 1 year; these trends continue with longer duration of use. Also can increase blood pressure and induce kidney injury. Risks are dose related","[""NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE"", ""NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE"", ""SUMATRIPTAN AND NAPROXEN SODIUM"", ""DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM"", ""NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE"", ""SUMATRIPTAN; NAPROXEN SODIUM"", ""NAPROXEN SODIUM"", ""NAPROXEN"", ""LANSOPRAZOLE; NAPROXEN"", ""NAPROXEN AND ESOMEPRAZOLE MAGNESIUM"", ""ESOMEPRAZOLE MAGNESIUM; NAPROXEN"", ""NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE""]",NAPROXEN,,
148,Oxaprozin,"Avoid chronic use, unless other alternatives are not effective and patient can take gastroprotective agent (proton-pump inhibitor or misoprostol)","Increased risk of gastrointestinal bleeding or peptic ulcer disease in high-risk groups, including those >75 years or taking oral or parenteral corticosteroids, anticoagulants, or antiplatelet agents; use of proton-pump inhibitor or misoprostol reduces but does not eliminate risk. Upper gastrointestinal ulcers, gross bleeding, or perforation caused by NSAIDs occur in ~1% of patients treated for 3-6 months and in ~2%-4% of patients treated for 1 year; these trends continue with longer duration of use. Also can increase blood pressure and induce kidney injury. Risks are dose related","[""OXAPROZIN POTASSIUM"", ""OXAPROZIN""]",OXAPROZIN,,
149,Piroxicam,"Avoid chronic use, unless other alternatives are not effective and patient can take gastroprotective agent (proton-pump inhibitor or misoprostol)","Increased risk of gastrointestinal bleeding or peptic ulcer disease in high-risk groups, including those >75 years or taking oral or parenteral corticosteroids, anticoagulants, or antiplatelet agents; use of proton-pump inhibitor or misoprostol reduces but does not eliminate risk. Upper gastrointestinal ulcers, gross bleeding, or perforation caused by NSAIDs occur in ~1% of patients treated for 3-6 months and in ~2%-4% of patients treated for 1 year; these trends continue with longer duration of use. Also can increase blood pressure and induce kidney injury. Risks are dose related","[""PIROXICAM""]",PIROXICAM,,
150,Sulindac,"Avoid chronic use, unless other alternatives are not effective and patient can take gastroprotective agent (proton-pump inhibitor or misoprostol)","Increased risk of gastrointestinal bleeding or peptic ulcer disease in high-risk groups, including those >75 years or taking oral or parenteral corticosteroids, anticoagulants, or antiplatelet agents; use of proton-pump inhibitor or misoprostol reduces but does not eliminate risk. Upper gastrointestinal ulcers, gross bleeding, or perforation caused by NSAIDs occur in ~1% of patients treated for 3-6 months and in ~2%-4% of patients treated for 1 year; these trends continue with longer duration of use. Also can increase blood pressure and induce kidney injury. Risks are dose related","[""SULINDAC""]",SULINDAC,,
151,Tolmetin,"Avoid chronic use, unless other alternatives are not effective and patient can take gastroprotective agent (proton-pump inhibitor or misoprostol)","Increased risk of gastrointestinal bleeding or peptic ulcer disease in high-risk groups, including those >75 years or taking oral or parenteral corticosteroids, anticoagulants, or antiplatelet agents; use of proton-pump inhibitor or misoprostol reduces but does not eliminate risk. Upper gastrointestinal ulcers, gross bleeding, or perforation caused by NSAIDs occur in ~1% of patients treated for 3-6 months and in ~2%-4% of patients treated for 1 year; these trends continue with longer duration of use. Also can increase blood pressure and induce kidney injury. Risks are dose related","[""TOLMETIN SODIUM""]",TOLMETIN,,
152,Indomethacin,Avoid,"Increased risk of gastrointestinal bleeding/peptic ulcer disease and acute kidney injury in older adults. Indomethacin is more likely than other NSAIDs to have adverse CNS effects. Of all the NSAIDs, indomethacin has the most adverse effects","[""INDOMETHACIN SODIUM"", ""INDOMETHACIN""]",INDOMETHACIN,,
153,Ketorolac,Avoid,Increased risk of gastrointestinal bleeding/peptic ulcer disease and acute kidney injury in older adults,"[""KETOROLAC TROMETHAMINE AND PHENYLEPHRINE HYDROCHLORIDE"", ""KETOROLAC TROMETHAMINE"", ""KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE""]",KETOROLAC,,
154,Carisoprodol,Avoid,"Most muscle relaxants poorly tolerated by older adults because some have anticholinergic adverse effects, sedation, increased risk of fractures; effectiveness at dosages tolerated by older adults questionable","[""ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE"", ""ASPIRIN; CARISOPRODOL"", ""CARISOPRODOL COMPOUND"", ""CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE"", ""CARISOPRODOL"", ""CARISOPRODOL AND ASPIRIN""]",CARISOPRODOL,,
155,Chlorzoxazone,Avoid,"Most muscle relaxants poorly tolerated by older adults because some have anticholinergic adverse effects, sedation, increased risk of fractures; effectiveness at dosages tolerated by older adults questionable","[""CHLORZOXAZONE""]",CHLORZOXAZONE,,
156,Cyclobenzaprine,Avoid,"Most muscle relaxants poorly tolerated by older adults because some have anticholinergic adverse effects, sedation, increased risk of fractures; effectiveness at dosages tolerated by older adults questionable","[""CYCLOBENZAPRINE HYDROCHLORIDE""]",CYCLOBENZAPRINE,,
157,Metaxalone,Avoid,"Most muscle relaxants poorly tolerated by older adults because some have anticholinergic adverse effects, sedation, increased risk of fractures; effectiveness at dosages tolerated by older adults questionable","[""METAXALONE""]",METHANTHELINE,,
158,Methocarbamol,Avoid,"Most muscle relaxants poorly tolerated by older adults because some have anticholinergic adverse effects, sedation, increased risk of fractures; effectiveness at dosages tolerated by older adults questionable","[""METHOCARBAMOL AND ASPIRIN"", ""METHOCARBAMOL"", ""ASPIRIN; METHOCARBAMOL""]",METHOCARBAMOL,,
159,Orphenadrine,Avoid,"Most muscle relaxants poorly tolerated by older adults because some have anticholinergic adverse effects, sedation, increased risk of fractures; effectiveness at dosages tolerated by older adults questionable","[""ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE"", ""ORPHENADRINE CITRATE"", ""ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE"", ""ORPHENADRINE HYDROCHLORIDE""]",ORPHENADRINE,,
160,Desmopressin ,Avoid as treatment of nocturia or nocturnal polyuria,High risk of hyponatremia; safer alternative treatments,"[""DESMOPRESSIN ACETATE PRESERVATIVE FREE"", ""DESMOPRESSIN ACETATE"", ""DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION)""]",DESMOPRESSIN,,
161,Aspirin for primary prevention of cardiovascular disease and colorectal cancer,Use with caution in adults ≥70 years,"Risk of major bleeding from aspirin increases markedly in older age. Several studies suggest lack of net benefit when used for primary prevention in older adult with cardiovascular risk factors, but evidence is not conclusive. Aspirin is generally indicated for secondary prevention in older adults with established cardiovascular disease",,ACETYLSALICYLIC ACID,,
162,Dabigatran,Use with caution for treatment of VTE or atrial fibrillation in adults ≥75 years,Increased risk of gastrointestinal bleeding compared with warfarin and reported rates with other direct oral anticoagulants when used for long-term treatment of VTE or atrial fibrillation in adults ≥75 years,,DABIGATRAN ETEXILATE,,
163,Rivaroxaban,Use with caution in adults ≥75 years,Increased risk of gastrointestinal bleeding compared with warfarin and reported rates with other direct oral anticoagulants when used for long-term treatment of VTE or atrial fibrillation in adults ≥75 years,,RIVAROXABAN,,
164,Prasugrel,Use with caution,"Increased risk of bleeding in older adults; benefit in highest-risk older adults (eg, those with prior myocardial infarction or diabetes mellitus) may offset risk when used for its approved indication of acute coronary syndrome to be managed with percutaneous coronary intervention",,PRASUGREL,,
165,Chlorpromazine,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,CHLORPROMAZINE,,
166,Droperidol,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,DROPERIDOL,,
167,Fluphenazine,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,FLUPHENAZINE,,
168,Haloperidol,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,HALOPERIDOL,,
169,Loxapine,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,LOXAPINE,,
170,Perphenazine,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,PERPHENAZINE,,
171,Pimozide,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,PIMOZIDE,,
172,Prochlorperazine,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,PROCHLORPERAZINE,,
173,Thioridazine,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,THIORIDAZINE,,
174,Thiothixene,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,THIOTHIXENE,,
175,Trifluoperazine,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,TRIFLUOPERAZINE,,
176,Aripiprazole,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,ARIPIPRAZOLE,,
177,Asenapine,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,ASENAPINE,,
178,Clozapine,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,CLOZAPINE,,
179,Iloperidone,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,ILOPERIDONE,,
180,Lurasidone,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,LURASIDONE,,
181,Olanzapine,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,OLANZAPINE,,
182,Paliperidone,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,PALIPERIDONE,,
183,Quetiapine,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,QUETIAPINE,,
184,Risperidone,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,RISPERIDONE,,
185,Ziprasidone,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,ZIPRASIDONE,,
186,Pimavanserin,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,,,
187,Carbamazepine,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,CARBAMAZEPINE,,
188,Chlorothiazide,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,CHLOROTHIAZIDE,,
189,Chlorthalidone,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,CHLORTHALIDONE,,
190,Indapamide,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,INDAPAMIDE,,
191,Hydrochlorothiazide,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,HYDROCHLOROTHIAZIDE,,
192,Methyclothiazide,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,METHYCLOTHIAZIDE,,
193,Metolazone,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,METOLAZONE,,
194,Bumetanide,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,BUMETANIDE,,
195,Furosemide,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,FUROSEMIDE,,
196,Ethacrynate,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,ETHACRYNIC ACID,,
197,Torsemide,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,TORASEMIDE,,
198,Amiloride Hydrochloride,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,AMILORIDE,,
199,Spironolactone,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,SPIRONOLACTONE,,
200,Triamterene,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,TRIAMTERENE,,
201,Acetazolamide,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,ACETAZOLAMIDE,,
202,Methazolamide,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,METHAZOLAMIDE,,
203,Mirtazapine,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,MIRTAZAPINE,,
204,Oxcarbazepine,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,OXCARBAZEPINE,,
205,Amitriptyline,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,AMITRIPTYLINE,,
206,Amoxapine,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,AMOXAPINE,,
207,Clomipramine,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,CLOMIPRAMINE,,
208,Desipramine,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,DESIPRAMINE,,
209,Doxepin,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,DOXEPIN,,
210,Imipramine,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,IMIPRAMINE,,
211,Nortriptyline,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,NORTRIPTYLINE,,
212,Paroxetine,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,PAROXETINE,,
213,Protriptyline,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,PROTRIPTYLINE,,
214,Trimipramine,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,TRIMIPRAMINE,,
215,Citalopram,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,CITALOPRAM,,
216,Escitalopram,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,ESCITALOPRAM,,
217,Fluoxetine,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,FLUOXETINE,,
218,Paroxetine,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,PAROXETINE,,
219,Sertraline,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,SERTRALINE,,
220,Desvenlafaxine,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,DESVENLAFAXINE,,
221,Duloxetine,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,DULOXETINE,,
222,Levomilnacipran,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,CHLORAMPHENICOL,,
223,Milnacipran,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,MILNACIPRAN,,
224,Venlafaxine,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,VENLAFAXINE,,
225,Tramadol,Use with caution,May exacerbate or cause SIADH or hyponatremia; monitor sodium level closely when starting or changing dosages in older adults,,TRAMADOL,,
226,Dextromethorphan/Quinidine,Use with caution,Limited efficacy in patients with behavioral symptoms of dementia (does not apply to treatment of PBA). May increase risk of falls and concerns with clinically significant drug interactions. Does not apply to treatment of pseudobulbar affect,,DEXTROMETHORPHAN,,
227,"Trimethoprim-
sulfamethoxazole",Use with caution in patients on ACEI or ARB and decreased creatinine clearance,Increased risk of hyperkalemia when used concurrently with an ACEI or ARB in presence of decreased creatinine clearance,,TRIMETHOPRIM,,
228,Ciprofloxacin,Doses used to treat common infections typically require reduction when CrCl <30 mL/min,"Increased risk of CNS effects (eg, seizures, confusion) and tendon rupture",,CIPROFLOXACIN,<30,
229,Trimethoprim-sulfamethoxazole,"Reduce dose if CrCl 15-29 mL/min
Avoid if CrCl <15 mL/min",Increased risk of worsening of renal function and hyperkalemia,,TRIMETHOPRIM,<30,
230,Amiloride,Avoid,Increased potassium and decreased sodium,,AMILORIDE,<30,
231,Apixaban,Avoid,Lack of evidence for efficacy and safety in patients with a CrCl <25 mL/min,,APIXABAN,<25,
232,Dabigatran,Avoid; dose adjustment advised when CrCl >30 mL/min in the presence of drug-drug interactions,Lack of evidence for efficacy and safety in individuals with a CrCl <30 mL/min. Label dose for patients with a CrCl 15-30 mL/min based on pharmacokinetic data,,DABIGATRAN ETEXILATE,<30,
233,Dofetilide,"Reduce dose if CrCl 20-59 mL/min
Avoid if CrCl <20 mL/min",QTc prolongation and torsade de pointes,,DOFETILIDE,<60,
234,Edoxaban,Avoid,Lack of evidence of efficacy or safety in patients with a CrCl <30 mL/min,,,"<15, >95",
235,Edoxaban,Reduce dose,Lack of evidence of efficacy or safety in patients with a CrCl <30 mL/min,,,15-50,
236,Enoxaparin,Reduce dose,Increased risk of bleeding,,ENOXAPARIN,<30,
237,Fondaparinux,Avoid,Increased risk of bleeding,,FONDAPARINUX SODIUM,<30,
238,Rivaroxaban,"Nonvalvular atrial fibrillation: reduce dose if CrCl 15-50 mL/min; avoid if CrCl <15 mL/min
Venous thromboembolism treatment and for VTE prophylaxis with hip or knee replacement: avoid if CrCl <30 mL/min",Lack of efficacy or safety evidence in patients with a CrCl <30 mL/min,,RIVAROXABAN,<50,
239,Spironolactone,Avoid,Increased potassium,,SPIRONOLACTONE,<30,
240,Triamterene,Avoid,Increased potassium and decreased sodium,,TRIAMTERENE,<30,
241,Duloxetine,Avoid,"Increased gastrointestinal adverse effects (nausea, diarrhea)",,DULOXETINE,<30,
242,Gabapentin,Reduce dose,CNS adverse effects,,GABAPENTIN,<60,
243,Levetiracetam,Reduce dose,CNS adverse effects,,LEVETIRACETAM,≤80,
244,Pregabalin,Reduce dose,CNS adverse effects,,PREGABALIN,<60,
245,Tramadol,"Immediate release: reduce dose
Extended release: avoid",CNS adverse effects,,TRAMADOL,<30,
246,Cimetidine,Reduce dose,Mental status changes,,CIMETIDINE,<50,
247,Famotidine,Reduce dose,Mental status changes,,FAMOTIDINE,<50,
248,Nizatidine,Reduce dose,Mental status changes,,NIZATIDINE,<50,
249,Ranitidine,Reduce dose,Mental status changes,,RANITIDINE,<50,
250,Colchicine,Reduce dose; monitor for adverse effects,"Gastrointestinal, neuromuscular, bone marrow toxicity",,COLCHICINE,<30,
251,Probenecid,Avoid,Loss of effectiveness,,PROBENECID,<30,
252,,Avoid,"Potential to promote fluid retention and/or exacerbate heart failure (NSAIDs and COX-2 inhibitors, nondihydropyridine CCBs, thiazolidinediones); potential to increase mortality in older adults with heart failure (cilostazol and dronedarone)",,CILOSTAZOL,,Heart failure with preserved ejection fraction
253,,Avoid,"Potential to promote fluid retention and/or exacerbate heart failure (NSAIDs and COX-2 inhibitors, nondihydropyridine CCBs, thiazolidinediones); potential to increase mortality in older adults with heart failure (cilostazol and dronedarone)",,ACETYLSALICYLIC ACID,,Heart failure with preserved ejection fraction
254,,Avoid,"Potential to promote fluid retention and/or exacerbate heart failure (NSAIDs and COX-2 inhibitors, nondihydropyridine CCBs, thiazolidinediones); potential to increase mortality in older adults with heart failure (cilostazol and dronedarone)",,DICLOFENAC,,Heart failure with preserved ejection fraction
255,,Avoid,"Potential to promote fluid retention and/or exacerbate heart failure (NSAIDs and COX-2 inhibitors, nondihydropyridine CCBs, thiazolidinediones); potential to increase mortality in older adults with heart failure (cilostazol and dronedarone)",,DIFLUNISAL,,Heart failure with preserved ejection fraction
256,,Avoid,"Potential to promote fluid retention and/or exacerbate heart failure (NSAIDs and COX-2 inhibitors, nondihydropyridine CCBs, thiazolidinediones); potential to increase mortality in older adults with heart failure (cilostazol and dronedarone)",,ETODOLAC,,Heart failure with preserved ejection fraction
257,,Avoid,"Potential to promote fluid retention and/or exacerbate heart failure (NSAIDs and COX-2 inhibitors, nondihydropyridine CCBs, thiazolidinediones); potential to increase mortality in older adults with heart failure (cilostazol and dronedarone)",,FENOPROFEN,,Heart failure with preserved ejection fraction
258,,Avoid,"Potential to promote fluid retention and/or exacerbate heart failure (NSAIDs and COX-2 inhibitors, nondihydropyridine CCBs, thiazolidinediones); potential to increase mortality in older adults with heart failure (cilostazol and dronedarone)",,IBUPROFEN,,Heart failure with preserved ejection fraction
259,,Avoid,"Potential to promote fluid retention and/or exacerbate heart failure (NSAIDs and COX-2 inhibitors, nondihydropyridine CCBs, thiazolidinediones); potential to increase mortality in older adults with heart failure (cilostazol and dronedarone)",,KETOPROFEN,,Heart failure with preserved ejection fraction
260,,Avoid,"Potential to promote fluid retention and/or exacerbate heart failure (NSAIDs and COX-2 inhibitors, nondihydropyridine CCBs, thiazolidinediones); potential to increase mortality in older adults with heart failure (cilostazol and dronedarone)",,MECLOFENAMIC ACID,,Heart failure with preserved ejection fraction
261,,Avoid,"Potential to promote fluid retention and/or exacerbate heart failure (NSAIDs and COX-2 inhibitors, nondihydropyridine CCBs, thiazolidinediones); potential to increase mortality in older adults with heart failure (cilostazol and dronedarone)",,MEFENAMIC ACID,,Heart failure with preserved ejection fraction
262,,Avoid,"Potential to promote fluid retention and/or exacerbate heart failure (NSAIDs and COX-2 inhibitors, nondihydropyridine CCBs, thiazolidinediones); potential to increase mortality in older adults with heart failure (cilostazol and dronedarone)",,MELOXICAM,,Heart failure with preserved ejection fraction
263,,Avoid,"Potential to promote fluid retention and/or exacerbate heart failure (NSAIDs and COX-2 inhibitors, nondihydropyridine CCBs, thiazolidinediones); potential to increase mortality in older adults with heart failure (cilostazol and dronedarone)",,NABUMETONE,,Heart failure with preserved ejection fraction
264,,Avoid,"Potential to promote fluid retention and/or exacerbate heart failure (NSAIDs and COX-2 inhibitors, nondihydropyridine CCBs, thiazolidinediones); potential to increase mortality in older adults with heart failure (cilostazol and dronedarone)",,NAPROXEN,,Heart failure with preserved ejection fraction
265,,Avoid,"Potential to promote fluid retention and/or exacerbate heart failure (NSAIDs and COX-2 inhibitors, nondihydropyridine CCBs, thiazolidinediones); potential to increase mortality in older adults with heart failure (cilostazol and dronedarone)",,OXAPROZIN,,Heart failure with preserved ejection fraction
266,,Avoid,"Potential to promote fluid retention and/or exacerbate heart failure (NSAIDs and COX-2 inhibitors, nondihydropyridine CCBs, thiazolidinediones); potential to increase mortality in older adults with heart failure (cilostazol and dronedarone)",,PIROXICAM,,Heart failure with preserved ejection fraction
267,,Avoid,"Potential to promote fluid retention and/or exacerbate heart failure (NSAIDs and COX-2 inhibitors, nondihydropyridine CCBs, thiazolidinediones); potential to increase mortality in older adults with heart failure (cilostazol and dronedarone)",,SULINDAC,,Heart failure with preserved ejection fraction
268,,Avoid,"Potential to promote fluid retention and/or exacerbate heart failure (NSAIDs and COX-2 inhibitors, nondihydropyridine CCBs, thiazolidinediones); potential to increase mortality in older adults with heart failure (cilostazol and dronedarone)",,TOLMETIN,,Heart failure with preserved ejection fraction
269,,Avoid,"Potential to promote fluid retention and/or exacerbate heart failure (NSAIDs and COX-2 inhibitors, nondihydropyridine CCBs, thiazolidinediones); potential to increase mortality in older adults with heart failure (cilostazol and dronedarone)",,CELECOXIB,,Heart failure with preserved ejection fraction
270,,Avoid,"Potential to promote fluid retention and/or exacerbate heart failure (NSAIDs and COX-2 inhibitors, nondihydropyridine CCBs, thiazolidinediones); potential to increase mortality in older adults with heart failure (cilostazol and dronedarone)",,CILOSTAZOL,,Heart failure with reduced ejection fraction
271,,Avoid,"Potential to promote fluid retention and/or exacerbate heart failure (NSAIDs and COX-2 inhibitors, nondihydropyridine CCBs, thiazolidinediones); potential to increase mortality in older adults with heart failure (cilostazol and dronedarone)",,DILTIAZEM,,Heart failure with reduced ejection fraction
272,,Avoid,"Potential to promote fluid retention and/or exacerbate heart failure (NSAIDs and COX-2 inhibitors, nondihydropyridine CCBs, thiazolidinediones); potential to increase mortality in older adults with heart failure (cilostazol and dronedarone)",,VERAPAMIL,,Heart failure with reduced ejection fraction
273,,Avoid,"Potential to promote fluid retention and/or exacerbate heart failure (NSAIDs and COX-2 inhibitors, nondihydropyridine CCBs, thiazolidinediones); potential to increase mortality in older adults with heart failure (cilostazol and dronedarone)",,ACETYLSALICYLIC ACID,,Heart failure with reduced ejection fraction
274,,Avoid,"Potential to promote fluid retention and/or exacerbate heart failure (NSAIDs and COX-2 inhibitors, nondihydropyridine CCBs, thiazolidinediones); potential to increase mortality in older adults with heart failure (cilostazol and dronedarone)",,DICLOFENAC,,Heart failure with reduced ejection fraction
275,,Avoid,"Potential to promote fluid retention and/or exacerbate heart failure (NSAIDs and COX-2 inhibitors, nondihydropyridine CCBs, thiazolidinediones); potential to increase mortality in older adults with heart failure (cilostazol and dronedarone)",,DIFLUNISAL,,Heart failure with reduced ejection fraction
276,,Avoid,"Potential to promote fluid retention and/or exacerbate heart failure (NSAIDs and COX-2 inhibitors, nondihydropyridine CCBs, thiazolidinediones); potential to increase mortality in older adults with heart failure (cilostazol and dronedarone)",,ETODOLAC,,Heart failure with reduced ejection fraction
277,,Avoid,"Potential to promote fluid retention and/or exacerbate heart failure (NSAIDs and COX-2 inhibitors, nondihydropyridine CCBs, thiazolidinediones); potential to increase mortality in older adults with heart failure (cilostazol and dronedarone)",,FENOPROFEN,,Heart failure with reduced ejection fraction
278,,Avoid,"Potential to promote fluid retention and/or exacerbate heart failure (NSAIDs and COX-2 inhibitors, nondihydropyridine CCBs, thiazolidinediones); potential to increase mortality in older adults with heart failure (cilostazol and dronedarone)",,IBUPROFEN,,Heart failure with reduced ejection fraction
279,,Avoid,"Potential to promote fluid retention and/or exacerbate heart failure (NSAIDs and COX-2 inhibitors, nondihydropyridine CCBs, thiazolidinediones); potential to increase mortality in older adults with heart failure (cilostazol and dronedarone)",,KETOPROFEN,,Heart failure with reduced ejection fraction
280,,Avoid,"Potential to promote fluid retention and/or exacerbate heart failure (NSAIDs and COX-2 inhibitors, nondihydropyridine CCBs, thiazolidinediones); potential to increase mortality in older adults with heart failure (cilostazol and dronedarone)",,MECLOFENAMIC ACID,,Heart failure with reduced ejection fraction
281,,Avoid,"Potential to promote fluid retention and/or exacerbate heart failure (NSAIDs and COX-2 inhibitors, nondihydropyridine CCBs, thiazolidinediones); potential to increase mortality in older adults with heart failure (cilostazol and dronedarone)",,MEFENAMIC ACID,,Heart failure with reduced ejection fraction
282,,Avoid,"Potential to promote fluid retention and/or exacerbate heart failure (NSAIDs and COX-2 inhibitors, nondihydropyridine CCBs, thiazolidinediones); potential to increase mortality in older adults with heart failure (cilostazol and dronedarone)",,MELOXICAM,,Heart failure with reduced ejection fraction
283,,Avoid,"Potential to promote fluid retention and/or exacerbate heart failure (NSAIDs and COX-2 inhibitors, nondihydropyridine CCBs, thiazolidinediones); potential to increase mortality in older adults with heart failure (cilostazol and dronedarone)",,NABUMETONE,,Heart failure with reduced ejection fraction
284,,Avoid,"Potential to promote fluid retention and/or exacerbate heart failure (NSAIDs and COX-2 inhibitors, nondihydropyridine CCBs, thiazolidinediones); potential to increase mortality in older adults with heart failure (cilostazol and dronedarone)",,NAPROXEN,,Heart failure with reduced ejection fraction
285,,Avoid,"Potential to promote fluid retention and/or exacerbate heart failure (NSAIDs and COX-2 inhibitors, nondihydropyridine CCBs, thiazolidinediones); potential to increase mortality in older adults with heart failure (cilostazol and dronedarone)",,OXAPROZIN,,Heart failure with reduced ejection fraction
286,,Avoid,"Potential to promote fluid retention and/or exacerbate heart failure (NSAIDs and COX-2 inhibitors, nondihydropyridine CCBs, thiazolidinediones); potential to increase mortality in older adults with heart failure (cilostazol and dronedarone)",,PIROXICAM,,Heart failure with reduced ejection fraction
287,,Avoid,"Potential to promote fluid retention and/or exacerbate heart failure (NSAIDs and COX-2 inhibitors, nondihydropyridine CCBs, thiazolidinediones); potential to increase mortality in older adults with heart failure (cilostazol and dronedarone)",,SULINDAC,,Heart failure with reduced ejection fraction
288,,Avoid,"Potential to promote fluid retention and/or exacerbate heart failure (NSAIDs and COX-2 inhibitors, nondihydropyridine CCBs, thiazolidinediones); potential to increase mortality in older adults with heart failure (cilostazol and dronedarone)",,TOLMETIN,,Heart failure with reduced ejection fraction
289,,Avoid,"Potential to promote fluid retention and/or exacerbate heart failure (NSAIDs and COX-2 inhibitors, nondihydropyridine CCBs, thiazolidinediones); potential to increase mortality in older adults with heart failure (cilostazol and dronedarone)",,CELECOXIB,,Heart failure with reduced ejection fraction
290,,Use with caution,Potential to promote fluid retention and/or exacerbate heart failure,,PIOGLITAZONE,,"Heart failure with reduced ejection fraction, asymptomatic"
291,,Use with caution,Potential to promote fluid retention and/or exacerbate heart failure,,ROSIGLITAZONE,,"Heart failure with reduced ejection fraction, asymptomatic"
292,,Use with caution,Potential to promote fluid retention and/or exacerbate heart failure,,DRONEDARONE,,"Heart failure with reduced ejection fraction, asymptomatic"
293,,Use with caution,Potential to promote fluid retention and/or exacerbate heart failure,,PIOGLITAZONE,,"Heart failure with preserved ejection fraction, asymptomatic"
294,,Use with caution,Potential to promote fluid retention and/or exacerbate heart failure,,ROSIGLITAZONE,,"Heart failure with preserved ejection fraction, asymptomatic"
295,,Use with caution,Potential to promote fluid retention and/or exacerbate heart failure,,DRONEDARONE,,"Heart failure with preserved ejection fraction, asymptomatic"
296,,Avoid,AChEIs cause bradycardia and should be avoided in older adults whose syncope may be due to bradycardia. Nonselective peripheral alpha-1 blockers cause orthostatic blood pressure changes and should be avoided in older adults whose syncope may be due to orthostatic hypotension. Tertiary TCAs and the antipsychotics listed increase the risk of orthostatic hypotension or bradycardia,,DONEPEZIL,,Syncope
297,,Avoid,AChEIs cause bradycardia and should be avoided in older adults whose syncope may be due to bradycardia. Nonselective peripheral alpha-1 blockers cause orthostatic blood pressure changes and should be avoided in older adults whose syncope may be due to orthostatic hypotension. Tertiary TCAs and the antipsychotics listed increase the risk of orthostatic hypotension or bradycardia,,RIVASTIGMINE,,Syncope
298,,Avoid,AChEIs cause bradycardia and should be avoided in older adults whose syncope may be due to bradycardia. Nonselective peripheral alpha-1 blockers cause orthostatic blood pressure changes and should be avoided in older adults whose syncope may be due to orthostatic hypotension. Tertiary TCAs and the antipsychotics listed increase the risk of orthostatic hypotension or bradycardia,,GALANTAMINE,,Syncope
299,,Avoid,AChEIs cause bradycardia and should be avoided in older adults whose syncope may be due to bradycardia. Nonselective peripheral alpha-1 blockers cause orthostatic blood pressure changes and should be avoided in older adults whose syncope may be due to orthostatic hypotension. Tertiary TCAs and the antipsychotics listed increase the risk of orthostatic hypotension or bradycardia,,TACRINE,,Syncope
300,,Avoid,AChEIs cause bradycardia and should be avoided in older adults whose syncope may be due to bradycardia. Nonselective peripheral alpha-1 blockers cause orthostatic blood pressure changes and should be avoided in older adults whose syncope may be due to orthostatic hypotension. Tertiary TCAs and the antipsychotics listed increase the risk of orthostatic hypotension or bradycardia,,DOXAZOSIN,,Syncope
301,,Avoid,AChEIs cause bradycardia and should be avoided in older adults whose syncope may be due to bradycardia. Nonselective peripheral alpha-1 blockers cause orthostatic blood pressure changes and should be avoided in older adults whose syncope may be due to orthostatic hypotension. Tertiary TCAs and the antipsychotics listed increase the risk of orthostatic hypotension or bradycardia,,PRAZOSIN,,Syncope
302,,Avoid,AChEIs cause bradycardia and should be avoided in older adults whose syncope may be due to bradycardia. Nonselective peripheral alpha-1 blockers cause orthostatic blood pressure changes and should be avoided in older adults whose syncope may be due to orthostatic hypotension. Tertiary TCAs and the antipsychotics listed increase the risk of orthostatic hypotension or bradycardia,,TERAZOSIN,,Syncope
303,,Avoid,AChEIs cause bradycardia and should be avoided in older adults whose syncope may be due to bradycardia. Nonselective peripheral alpha-1 blockers cause orthostatic blood pressure changes and should be avoided in older adults whose syncope may be due to orthostatic hypotension. Tertiary TCAs and the antipsychotics listed increase the risk of orthostatic hypotension or bradycardia,,AMITRIPTYLINE,,Syncope
304,,Avoid,AChEIs cause bradycardia and should be avoided in older adults whose syncope may be due to bradycardia. Nonselective peripheral alpha-1 blockers cause orthostatic blood pressure changes and should be avoided in older adults whose syncope may be due to orthostatic hypotension. Tertiary TCAs and the antipsychotics listed increase the risk of orthostatic hypotension or bradycardia,,IMIPRAMINE,,Syncope
305,,Avoid,AChEIs cause bradycardia and should be avoided in older adults whose syncope may be due to bradycardia. Nonselective peripheral alpha-1 blockers cause orthostatic blood pressure changes and should be avoided in older adults whose syncope may be due to orthostatic hypotension. Tertiary TCAs and the antipsychotics listed increase the risk of orthostatic hypotension or bradycardia,,CLOMIPRAMINE,,Syncope
306,,Avoid,AChEIs cause bradycardia and should be avoided in older adults whose syncope may be due to bradycardia. Nonselective peripheral alpha-1 blockers cause orthostatic blood pressure changes and should be avoided in older adults whose syncope may be due to orthostatic hypotension. Tertiary TCAs and the antipsychotics listed increase the risk of orthostatic hypotension or bradycardia,,TRIMIPRAMINE,,Syncope
307,,Avoid,AChEIs cause bradycardia and should be avoided in older adults whose syncope may be due to bradycardia. Nonselective peripheral alpha-1 blockers cause orthostatic blood pressure changes and should be avoided in older adults whose syncope may be due to orthostatic hypotension. Tertiary TCAs and the antipsychotics listed increase the risk of orthostatic hypotension or bradycardia,,DOXEPIN,,Syncope
308,,Avoid,AChEIs cause bradycardia and should be avoided in older adults whose syncope may be due to bradycardia. Nonselective peripheral alpha-1 blockers cause orthostatic blood pressure changes and should be avoided in older adults whose syncope may be due to orthostatic hypotension. Tertiary TCAs and the antipsychotics listed increase the risk of orthostatic hypotension or bradycardia,,CHLORPROMAZINE,,Syncope
309,,Avoid,AChEIs cause bradycardia and should be avoided in older adults whose syncope may be due to bradycardia. Nonselective peripheral alpha-1 blockers cause orthostatic blood pressure changes and should be avoided in older adults whose syncope may be due to orthostatic hypotension. Tertiary TCAs and the antipsychotics listed increase the risk of orthostatic hypotension or bradycardia,,THIORIDAZINE,,Syncope
310,,Avoid,AChEIs cause bradycardia and should be avoided in older adults whose syncope may be due to bradycardia. Nonselective peripheral alpha-1 blockers cause orthostatic blood pressure changes and should be avoided in older adults whose syncope may be due to orthostatic hypotension. Tertiary TCAs and the antipsychotics listed increase the risk of orthostatic hypotension or bradycardia,,OLANZAPINE,,Syncope
311,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,DISOPYRAMIDE,,Delirium
312,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,MEPYRAMINE,,Delirium
313,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,TRIPROLIDINE,,Delirium
314,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,AMITRIPTYLINE,,Delirium
315,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,AMOXAPINE,,Delirium
316,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,CLOMIPRAMINE,,Delirium
317,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,DESIPRAMINE,,Delirium
318,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,DOXEPIN,,Delirium
319,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,DARIFENACIN,,Delirium
320,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,IMIPRAMINE,,Delirium
321,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,FESOTERODINE,,Delirium
322,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,NORTRIPTYLINE,,Delirium
323,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,FLAVOXATE,,Delirium
324,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,PAROXETINE,,Delirium
325,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,OXYBUTYNIN,,Delirium
326,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,PROTRIPTYLINE,,Delirium
327,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,SOLIFENACIN,,Delirium
328,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,TRIMIPRAMINE,,Delirium
329,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,TOLTERODINE,,Delirium
330,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,TROSPIUM,,Delirium
331,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,PROCHLORPERAZINE,,Delirium
332,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,PROMETHAZINE,,Delirium
333,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,BENZATROPINE,,Delirium
334,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,TRIHEXYPHENIDYL,,Delirium
335,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,BROMPHENIRAMINE,,Delirium
336,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,CARBINOXAMINE,,Delirium
337,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,CHLORPROMAZINE,,Delirium
338,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,CHLORPHENIRAMINE,,Delirium
339,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,CLOZAPINE,,Delirium
340,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,CLEMASTINE,,Delirium
341,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,CYPROHEPTADINE,,Delirium
342,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,OLANZAPINE,,Delirium
343,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,DEXBROMPHENIRAMINE,,Delirium
344,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,CHLORPHENIRAMINE,,Delirium
345,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,THIORIDAZINE,,Delirium
346,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,DIMENHYDRINATE,,Delirium
347,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,TRIFLUOPERAZINE,,Delirium
348,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,DIPHENHYDRAMINE,,Delirium
349,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,DOXYLAMINE,,Delirium
350,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,HYDROXYZINE,,Delirium
351,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,ATROPINE,,Delirium
352,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,MECLIZINE,,Delirium
353,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,,,Delirium
354,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,,,Delirium
355,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,METHYLSCOPOLAMINE,,Delirium
356,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,DICYCLOMINE,,Delirium
357,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,HOMATROPINE METHYLBROMIDE,,Delirium
358,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,HYOSCYAMINE,,Delirium
359,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,CYCLOBENZAPRINE,,Delirium
360,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,METHYLSCOPOLAMINE,,Delirium
361,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,ORPHENADRINE,,Delirium
362,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,PROPANTHELINE,,Delirium
363,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,ALPRAZOLAM,,Delirium
364,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,ESTAZOLAM,,Delirium
365,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,LORAZEPAM,,Delirium
366,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,OXAZEPAM,,Delirium
367,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,TEMAZEPAM,,Delirium
368,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,TRIAZOLAM,,Delirium
369,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,CHLORDIAZEPOXIDE,,Delirium
370,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,CLONAZEPAM,,Delirium
371,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,CLORAZEPATE,,Delirium
372,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,DIAZEPAM,,Delirium
373,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,FLURAZEPAM,,Delirium
374,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,QUAZEPAM,,Delirium
375,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,CHLORPROMAZINE,,Delirium
376,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,DROPERIDOL,,Delirium
377,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,FLUPHENAZINE,,Delirium
378,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,HALOPERIDOL,,Delirium
379,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,LOXAPINE,,Delirium
380,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,PERPHENAZINE,,Delirium
381,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,PIMOZIDE,,Delirium
382,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,PROCHLORPERAZINE,,Delirium
383,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,THIORIDAZINE,,Delirium
384,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,THIOTHIXENE,,Delirium
385,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,TRIFLUOPERAZINE,,Delirium
386,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,ARIPIPRAZOLE,,Delirium
387,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,ASENAPINE,,Delirium
388,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,CLOZAPINE,,Delirium
389,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,ILOPERIDONE,,Delirium
390,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,LURASIDONE,,Delirium
391,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,OLANZAPINE,,Delirium
392,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,PALIPERIDONE,,Delirium
393,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,QUETIAPINE,,Delirium
394,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,RISPERIDONE,,Delirium
395,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,ZIPRASIDONE,,Delirium
396,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,,,Delirium
397,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,HYDROCORTISONE,,Delirium
398,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,HYDROCORTISONE,,Delirium
399,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,BETAMETHASONE,,Delirium
400,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,PREDNISONE,,Delirium
401,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,PREDNISOLONE,,Delirium
402,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,TRIAMCINOLONE,,Delirium
403,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,METHYLPREDNISOLONE,,Delirium
404,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,DEXAMETHASONE,,Delirium
405,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,,,Delirium
406,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,CIMETIDINE,,Delirium
407,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,FAMOTIDINE,,Delirium
408,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,NIZATIDINE,,Delirium
409,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,RANITIDINE,,Delirium
410,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,MEPERIDINE,,Delirium
411,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,ESZOPICLONE,,Delirium
412,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,ZALEPLON,,Delirium
413,,Avoid,"Avoid in older adults with or at high risk of delirium because of potential of inducing or worsening delirium.
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,ZOLPIDEM,,Delirium
414,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,DISOPYRAMIDE,,Dementia or cognitive impairment
415,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,MEPYRAMINE,,Dementia or cognitive impairment
416,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,TRIPROLIDINE,,Dementia or cognitive impairment
417,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,AMITRIPTYLINE,,Dementia or cognitive impairment
418,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,AMOXAPINE,,Dementia or cognitive impairment
419,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,CLOMIPRAMINE,,Dementia or cognitive impairment
420,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,DESIPRAMINE,,Dementia or cognitive impairment
421,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,DOXEPIN,,Dementia or cognitive impairment
422,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,DARIFENACIN,,Dementia or cognitive impairment
423,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,IMIPRAMINE,,Dementia or cognitive impairment
424,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,FESOTERODINE,,Dementia or cognitive impairment
425,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,NORTRIPTYLINE,,Dementia or cognitive impairment
426,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,FLAVOXATE,,Dementia or cognitive impairment
427,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,PAROXETINE,,Dementia or cognitive impairment
428,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,OXYBUTYNIN,,Dementia or cognitive impairment
429,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,PROTRIPTYLINE,,Dementia or cognitive impairment
430,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,SOLIFENACIN,,Dementia or cognitive impairment
431,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,TRIMIPRAMINE,,Dementia or cognitive impairment
432,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,TOLTERODINE,,Dementia or cognitive impairment
433,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,TROSPIUM,,Dementia or cognitive impairment
434,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,PROCHLORPERAZINE,,Dementia or cognitive impairment
435,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,PROMETHAZINE,,Dementia or cognitive impairment
436,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,BENZATROPINE,,Dementia or cognitive impairment
437,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,TRIHEXYPHENIDYL,,Dementia or cognitive impairment
438,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,BROMPHENIRAMINE,,Dementia or cognitive impairment
439,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,CARBINOXAMINE,,Dementia or cognitive impairment
440,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,CHLORPROMAZINE,,Dementia or cognitive impairment
441,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,CHLORPHENIRAMINE,,Dementia or cognitive impairment
442,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,CLOZAPINE,,Dementia or cognitive impairment
443,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,CLEMASTINE,,Dementia or cognitive impairment
444,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,CYPROHEPTADINE,,Dementia or cognitive impairment
445,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,OLANZAPINE,,Dementia or cognitive impairment
446,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,DEXBROMPHENIRAMINE,,Dementia or cognitive impairment
447,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,CHLORPHENIRAMINE,,Dementia or cognitive impairment
448,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,THIORIDAZINE,,Dementia or cognitive impairment
449,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,DIMENHYDRINATE,,Dementia or cognitive impairment
450,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,TRIFLUOPERAZINE,,Dementia or cognitive impairment
451,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,DIPHENHYDRAMINE,,Dementia or cognitive impairment
452,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,DOXYLAMINE,,Dementia or cognitive impairment
453,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,HYDROXYZINE,,Dementia or cognitive impairment
454,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,ATROPINE,,Dementia or cognitive impairment
455,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,MECLIZINE,,Dementia or cognitive impairment
456,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,,,Dementia or cognitive impairment
457,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,,,Dementia or cognitive impairment
458,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,METHYLSCOPOLAMINE,,Dementia or cognitive impairment
459,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,DICYCLOMINE,,Dementia or cognitive impairment
460,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,HOMATROPINE METHYLBROMIDE,,Dementia or cognitive impairment
461,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,HYOSCYAMINE,,Dementia or cognitive impairment
462,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,CYCLOBENZAPRINE,,Dementia or cognitive impairment
463,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,METHYLSCOPOLAMINE,,Dementia or cognitive impairment
464,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,ORPHENADRINE,,Dementia or cognitive impairment
465,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,PROPANTHELINE,,Dementia or cognitive impairment
466,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,ALPRAZOLAM,,Dementia or cognitive impairment
467,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,ESTAZOLAM,,Dementia or cognitive impairment
468,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,LORAZEPAM,,Dementia or cognitive impairment
469,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,OXAZEPAM,,Dementia or cognitive impairment
470,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,TEMAZEPAM,,Dementia or cognitive impairment
471,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,TRIAZOLAM,,Dementia or cognitive impairment
472,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,CHLORDIAZEPOXIDE,,Dementia or cognitive impairment
473,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,CLONAZEPAM,,Dementia or cognitive impairment
474,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,CLORAZEPATE,,Dementia or cognitive impairment
475,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,DIAZEPAM,,Dementia or cognitive impairment
476,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,FLURAZEPAM,,Dementia or cognitive impairment
477,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,QUAZEPAM,,Dementia or cognitive impairment
478,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,ESZOPICLONE,,Dementia or cognitive impairment
479,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,ZALEPLON,,Dementia or cognitive impairment
480,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,ZOLPIDEM,,Dementia or cognitive impairment
481,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,CHLORPROMAZINE,,Dementia or cognitive impairment
482,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,DROPERIDOL,,Dementia or cognitive impairment
483,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,FLUPHENAZINE,,Dementia or cognitive impairment
484,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,HALOPERIDOL,,Dementia or cognitive impairment
485,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,LOXAPINE,,Dementia or cognitive impairment
486,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,PERPHENAZINE,,Dementia or cognitive impairment
487,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,PIMOZIDE,,Dementia or cognitive impairment
488,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,PROCHLORPERAZINE,,Dementia or cognitive impairment
489,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,THIORIDAZINE,,Dementia or cognitive impairment
490,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,THIOTHIXENE,,Dementia or cognitive impairment
491,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,TRIFLUOPERAZINE,,Dementia or cognitive impairment
492,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,ARIPIPRAZOLE,,Dementia or cognitive impairment
493,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,ASENAPINE,,Dementia or cognitive impairment
494,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,CLOZAPINE,,Dementia or cognitive impairment
495,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,ILOPERIDONE,,Dementia or cognitive impairment
496,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,LURASIDONE,,Dementia or cognitive impairment
497,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,OLANZAPINE,,Dementia or cognitive impairment
498,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,PALIPERIDONE,,Dementia or cognitive impairment
499,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,QUETIAPINE,,Dementia or cognitive impairment
500,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,RISPERIDONE,,Dementia or cognitive impairment
501,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,ZIPRASIDONE,,Dementia or cognitive impairment
502,,Avoid,"Avoid because of adverse CNS effects
Avoid antipsychotics for behavioral problems of dementia and/or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. Antipsychotics are associated with greater risk of cerebrovascular accident (stroke) and mortality in persons with dementia.",,,,Dementia or cognitive impairment
503,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,PHENYTOIN,,History of falls or fractures
504,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,VALPROIC ACID,,History of falls or fractures
505,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,PHENOBARBITAL,,History of falls or fractures
506,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,LAMOTRIGINE,,History of falls or fractures
507,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,CARBAMAZEPINE,,History of falls or fractures
508,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,TOPIRAMATE,,History of falls or fractures
509,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,OXCARBAZEPINE,,History of falls or fractures
510,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,ZONISAMIDE,,History of falls or fractures
511,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,GABAPENTIN,,History of falls or fractures
512,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,LEVETIRACETAM,,History of falls or fractures
513,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,PREGABALIN,,History of falls or fractures
514,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,CLONAZEPAM,,History of falls or fractures
515,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,LACOSAMIDE,,History of falls or fractures
516,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,RUFINAMIDE,,History of falls or fractures
517,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,VIGABATRIN,,History of falls or fractures
518,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,CHLORPROMAZINE,,History of falls or fractures
519,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,DROPERIDOL,,History of falls or fractures
520,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,FLUPHENAZINE,,History of falls or fractures
521,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,HALOPERIDOL,,History of falls or fractures
522,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,LOXAPINE,,History of falls or fractures
523,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,PERPHENAZINE,,History of falls or fractures
524,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,PIMOZIDE,,History of falls or fractures
525,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,PROCHLORPERAZINE,,History of falls or fractures
526,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,THIORIDAZINE,,History of falls or fractures
527,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,THIOTHIXENE,,History of falls or fractures
528,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,TRIFLUOPERAZINE,,History of falls or fractures
529,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,ARIPIPRAZOLE,,History of falls or fractures
530,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,ASENAPINE,,History of falls or fractures
531,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,CLOZAPINE,,History of falls or fractures
532,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,ILOPERIDONE,,History of falls or fractures
533,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,LURASIDONE,,History of falls or fractures
534,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,OLANZAPINE,,History of falls or fractures
535,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,PALIPERIDONE,,History of falls or fractures
536,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,QUETIAPINE,,History of falls or fractures
537,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,RISPERIDONE,,History of falls or fractures
538,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,ZIPRASIDONE,,History of falls or fractures
539,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,,,History of falls or fractures
540,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,ALPRAZOLAM,,History of falls or fractures
541,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,ESTAZOLAM,,History of falls or fractures
542,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,LORAZEPAM,,History of falls or fractures
543,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,OXAZEPAM,,History of falls or fractures
544,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,TEMAZEPAM,,History of falls or fractures
545,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,TRIAZOLAM,,History of falls or fractures
546,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,CHLORDIAZEPOXIDE,,History of falls or fractures
547,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,CLONAZEPAM,,History of falls or fractures
548,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,CLORAZEPATE,,History of falls or fractures
549,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,DIAZEPAM,,History of falls or fractures
550,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,FLURAZEPAM,,History of falls or fractures
551,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,QUAZEPAM,,History of falls or fractures
552,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,ESZOPICLONE,,History of falls or fractures
553,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,ZALEPLON,,History of falls or fractures
554,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,ZOLPIDEM,,History of falls or fractures
555,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,AMITRIPTYLINE,,History of falls or fractures
556,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,AMOXAPINE,,History of falls or fractures
557,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,CLOMIPRAMINE,,History of falls or fractures
558,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,DESIPRAMINE,,History of falls or fractures
559,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,DOXEPIN,,History of falls or fractures
560,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,IMIPRAMINE,,History of falls or fractures
561,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,NORTRIPTYLINE,,History of falls or fractures
562,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,PAROXETINE,,History of falls or fractures
563,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,PROTRIPTYLINE,,History of falls or fractures
564,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,TRIMIPRAMINE,,History of falls or fractures
565,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,CITALOPRAM,,History of falls or fractures
566,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,ESCITALOPRAM,,History of falls or fractures
567,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,FLUOXETINE,,History of falls or fractures
568,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,PAROXETINE,,History of falls or fractures
569,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,SERTRALINE,,History of falls or fractures
570,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,DESVENLAFAXINE,,History of falls or fractures
571,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,DULOXETINE,,History of falls or fractures
572,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,CHLORAMPHENICOL,,History of falls or fractures
573,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,MILNACIPRAN,,History of falls or fractures
574,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,VENLAFAXINE,,History of falls or fractures
575,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,CHLORDIAZEPOXIDE,,History of falls or fractures
576,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,HEROIN,,History of falls or fractures
577,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,CODEINE,,History of falls or fractures
578,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,OXYCODONE,,History of falls or fractures
579,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,HYDROCODONE,,History of falls or fractures
580,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,TRAMADOL,,History of falls or fractures
581,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,MORPHINE,,History of falls or fractures
582,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,HYDROMORPHONE,,History of falls or fractures
583,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,FENTANYL,,History of falls or fractures
584,,Avoid,"May cause ataxia, impaired psychomotor function, syncope, additional falls; shorteracting benzodiazepines are not safer than long-acting ones.
If one of the drugs must be used, consider reducing use of other CNS-active medications that increase risk of falls and fractures (ie, antiepileptics, opioid-receptor agonists, antipsychotics, antidepressants, nonbenzodiazepine and benzodiazepine receptor agonist hypnotics, other sedatives/hypnotics) and implement other strategies to reduce fall risk. Data for antidepressants are mixed but no compelling evidence that certain antidepressants confer less fall risk than others.",,DOXAZOSIN,,History of falls or fractures
585,,Avoid,"Dopamine-receptor antagonists with potential to worsen parkinsonian symptoms.
Exceptions: Pimavanserin and clozapine appear to be less likely to precipitate worsening of Parkinson disease. Quetiapine has only been studied in low-quality clinical trials with efficacy comparable to that of placebo in five trials and to that of clozapine in two others.",,METOCLOPRAMIDE,,Parkinson Disease
586,,Avoid,"Dopamine-receptor antagonists with potential to worsen parkinsonian symptoms.
Exceptions: Pimavanserin and clozapine appear to be less likely to precipitate worsening of Parkinson disease. Quetiapine has only been studied in low-quality clinical trials with efficacy comparable to that of placebo in five trials and to that of clozapine in two others.",,PROCHLORPERAZINE,,Parkinson Disease
587,,Avoid,"Dopamine-receptor antagonists with potential to worsen parkinsonian symptoms.
Exceptions: Pimavanserin and clozapine appear to be less likely to precipitate worsening of Parkinson disease. Quetiapine has only been studied in low-quality clinical trials with efficacy comparable to that of placebo in five trials and to that of clozapine in two others.",,PROMETHAZINE,,Parkinson Disease
588,,Avoid,"Dopamine-receptor antagonists with potential to worsen parkinsonian symptoms.
Exceptions: Pimavanserin and clozapine appear to be less likely to precipitate worsening of Parkinson disease. Quetiapine has only been studied in low-quality clinical trials with efficacy comparable to that of placebo in five trials and to that of clozapine in two others.",,CHLORPROMAZINE,,Parkinson Disease
589,,Avoid,"Dopamine-receptor antagonists with potential to worsen parkinsonian symptoms.
Exceptions: Pimavanserin and clozapine appear to be less likely to precipitate worsening of Parkinson disease. Quetiapine has only been studied in low-quality clinical trials with efficacy comparable to that of placebo in five trials and to that of clozapine in two others.",,DROPERIDOL,,Parkinson Disease
590,,Avoid,"Dopamine-receptor antagonists with potential to worsen parkinsonian symptoms.
Exceptions: Pimavanserin and clozapine appear to be less likely to precipitate worsening of Parkinson disease. Quetiapine has only been studied in low-quality clinical trials with efficacy comparable to that of placebo in five trials and to that of clozapine in two others.",,FLUPHENAZINE,,Parkinson Disease
591,,Avoid,"Dopamine-receptor antagonists with potential to worsen parkinsonian symptoms.
Exceptions: Pimavanserin and clozapine appear to be less likely to precipitate worsening of Parkinson disease. Quetiapine has only been studied in low-quality clinical trials with efficacy comparable to that of placebo in five trials and to that of clozapine in two others.",,HALOPERIDOL,,Parkinson Disease
592,,Avoid,"Dopamine-receptor antagonists with potential to worsen parkinsonian symptoms.
Exceptions: Pimavanserin and clozapine appear to be less likely to precipitate worsening of Parkinson disease. Quetiapine has only been studied in low-quality clinical trials with efficacy comparable to that of placebo in five trials and to that of clozapine in two others.",,LOXAPINE,,Parkinson Disease
593,,Avoid,"Dopamine-receptor antagonists with potential to worsen parkinsonian symptoms.
Exceptions: Pimavanserin and clozapine appear to be less likely to precipitate worsening of Parkinson disease. Quetiapine has only been studied in low-quality clinical trials with efficacy comparable to that of placebo in five trials and to that of clozapine in two others.",,PERPHENAZINE,,Parkinson Disease
594,,Avoid,"Dopamine-receptor antagonists with potential to worsen parkinsonian symptoms.
Exceptions: Pimavanserin and clozapine appear to be less likely to precipitate worsening of Parkinson disease. Quetiapine has only been studied in low-quality clinical trials with efficacy comparable to that of placebo in five trials and to that of clozapine in two others.",,PIMOZIDE,,Parkinson Disease
595,,Avoid,"Dopamine-receptor antagonists with potential to worsen parkinsonian symptoms.
Exceptions: Pimavanserin and clozapine appear to be less likely to precipitate worsening of Parkinson disease. Quetiapine has only been studied in low-quality clinical trials with efficacy comparable to that of placebo in five trials and to that of clozapine in two others.",,PROCHLORPERAZINE,,Parkinson Disease
596,,Avoid,"Dopamine-receptor antagonists with potential to worsen parkinsonian symptoms.
Exceptions: Pimavanserin and clozapine appear to be less likely to precipitate worsening of Parkinson disease. Quetiapine has only been studied in low-quality clinical trials with efficacy comparable to that of placebo in five trials and to that of clozapine in two others.",,THIORIDAZINE,,Parkinson Disease
597,,Avoid,"Dopamine-receptor antagonists with potential to worsen parkinsonian symptoms.
Exceptions: Pimavanserin and clozapine appear to be less likely to precipitate worsening of Parkinson disease. Quetiapine has only been studied in low-quality clinical trials with efficacy comparable to that of placebo in five trials and to that of clozapine in two others.",,THIOTHIXENE,,Parkinson Disease
598,,Avoid,"Dopamine-receptor antagonists with potential to worsen parkinsonian symptoms.
Exceptions: Pimavanserin and clozapine appear to be less likely to precipitate worsening of Parkinson disease. Quetiapine has only been studied in low-quality clinical trials with efficacy comparable to that of placebo in five trials and to that of clozapine in two others.",,TRIFLUOPERAZINE,,Parkinson Disease
599,,Avoid,"Dopamine-receptor antagonists with potential to worsen parkinsonian symptoms.
Exceptions: Pimavanserin and clozapine appear to be less likely to precipitate worsening of Parkinson disease. Quetiapine has only been studied in low-quality clinical trials with efficacy comparable to that of placebo in five trials and to that of clozapine in two others.",,ARIPIPRAZOLE,,Parkinson Disease
600,,Avoid,"Dopamine-receptor antagonists with potential to worsen parkinsonian symptoms.
Exceptions: Pimavanserin and clozapine appear to be less likely to precipitate worsening of Parkinson disease. Quetiapine has only been studied in low-quality clinical trials with efficacy comparable to that of placebo in five trials and to that of clozapine in two others.",,ASENAPINE,,Parkinson Disease
601,,Avoid,"Dopamine-receptor antagonists with potential to worsen parkinsonian symptoms.
Exceptions: Pimavanserin and clozapine appear to be less likely to precipitate worsening of Parkinson disease. Quetiapine has only been studied in low-quality clinical trials with efficacy comparable to that of placebo in five trials and to that of clozapine in two others.",,ILOPERIDONE,,Parkinson Disease
602,,Avoid,"Dopamine-receptor antagonists with potential to worsen parkinsonian symptoms.
Exceptions: Pimavanserin and clozapine appear to be less likely to precipitate worsening of Parkinson disease. Quetiapine has only been studied in low-quality clinical trials with efficacy comparable to that of placebo in five trials and to that of clozapine in two others.",,LURASIDONE,,Parkinson Disease
603,,Avoid,"Dopamine-receptor antagonists with potential to worsen parkinsonian symptoms.
Exceptions: Pimavanserin and clozapine appear to be less likely to precipitate worsening of Parkinson disease. Quetiapine has only been studied in low-quality clinical trials with efficacy comparable to that of placebo in five trials and to that of clozapine in two others.",,OLANZAPINE,,Parkinson Disease
604,,Avoid,"Dopamine-receptor antagonists with potential to worsen parkinsonian symptoms.
Exceptions: Pimavanserin and clozapine appear to be less likely to precipitate worsening of Parkinson disease. Quetiapine has only been studied in low-quality clinical trials with efficacy comparable to that of placebo in five trials and to that of clozapine in two others.",,PALIPERIDONE,,Parkinson Disease
605,,Avoid,"Dopamine-receptor antagonists with potential to worsen parkinsonian symptoms.
Exceptions: Pimavanserin and clozapine appear to be less likely to precipitate worsening of Parkinson disease. Quetiapine has only been studied in low-quality clinical trials with efficacy comparable to that of placebo in five trials and to that of clozapine in two others.",,RISPERIDONE,,Parkinson Disease
606,,Avoid,"Dopamine-receptor antagonists with potential to worsen parkinsonian symptoms.
Exceptions: Pimavanserin and clozapine appear to be less likely to precipitate worsening of Parkinson disease. Quetiapine has only been studied in low-quality clinical trials with efficacy comparable to that of placebo in five trials and to that of clozapine in two others.",,ZIPRASIDONE,,Parkinson Disease
607,,Avoid unless other alternatives are not effective and patient can take gastroprotective agent (i.e. proton-pump inhibitor or misoprostol),May exacerbate existing ulcers or cause new/additional ulcers,,ACETYLSALICYLIC ACID,,History of gastric or duodenal ulcers
608,,Avoid unless other alternatives are not effective and patient can take gastroprotective agent (i.e. proton-pump inhibitor or misoprostol),May exacerbate existing ulcers or cause new/additional ulcers,,DICLOFENAC,,History of gastric or duodenal ulcers
609,,Avoid unless other alternatives are not effective and patient can take gastroprotective agent (i.e. proton-pump inhibitor or misoprostol),May exacerbate existing ulcers or cause new/additional ulcers,,DIFLUNISAL,,History of gastric or duodenal ulcers
610,,Avoid unless other alternatives are not effective and patient can take gastroprotective agent (i.e. proton-pump inhibitor or misoprostol),May exacerbate existing ulcers or cause new/additional ulcers,,ETODOLAC,,History of gastric or duodenal ulcers
611,,Avoid unless other alternatives are not effective and patient can take gastroprotective agent (i.e. proton-pump inhibitor or misoprostol),May exacerbate existing ulcers or cause new/additional ulcers,,FENOPROFEN,,History of gastric or duodenal ulcers
612,,Avoid unless other alternatives are not effective and patient can take gastroprotective agent (i.e. proton-pump inhibitor or misoprostol),May exacerbate existing ulcers or cause new/additional ulcers,,IBUPROFEN,,History of gastric or duodenal ulcers
613,,Avoid unless other alternatives are not effective and patient can take gastroprotective agent (i.e. proton-pump inhibitor or misoprostol),May exacerbate existing ulcers or cause new/additional ulcers,,KETOPROFEN,,History of gastric or duodenal ulcers
614,,Avoid unless other alternatives are not effective and patient can take gastroprotective agent (i.e. proton-pump inhibitor or misoprostol),May exacerbate existing ulcers or cause new/additional ulcers,,MECLOFENAMIC ACID,,History of gastric or duodenal ulcers
615,,Avoid unless other alternatives are not effective and patient can take gastroprotective agent (i.e. proton-pump inhibitor or misoprostol),May exacerbate existing ulcers or cause new/additional ulcers,,MEFENAMIC ACID,,History of gastric or duodenal ulcers
616,,Avoid unless other alternatives are not effective and patient can take gastroprotective agent (i.e. proton-pump inhibitor or misoprostol),May exacerbate existing ulcers or cause new/additional ulcers,,MELOXICAM,,History of gastric or duodenal ulcers
617,,Avoid unless other alternatives are not effective and patient can take gastroprotective agent (i.e. proton-pump inhibitor or misoprostol),May exacerbate existing ulcers or cause new/additional ulcers,,NABUMETONE,,History of gastric or duodenal ulcers
618,,Avoid unless other alternatives are not effective and patient can take gastroprotective agent (i.e. proton-pump inhibitor or misoprostol),May exacerbate existing ulcers or cause new/additional ulcers,,NAPROXEN,,History of gastric or duodenal ulcers
619,,Avoid unless other alternatives are not effective and patient can take gastroprotective agent (i.e. proton-pump inhibitor or misoprostol),May exacerbate existing ulcers or cause new/additional ulcers,,OXAPROZIN,,History of gastric or duodenal ulcers
620,,Avoid unless other alternatives are not effective and patient can take gastroprotective agent (i.e. proton-pump inhibitor or misoprostol),May exacerbate existing ulcers or cause new/additional ulcers,,PIROXICAM,,History of gastric or duodenal ulcers
621,,Avoid unless other alternatives are not effective and patient can take gastroprotective agent (i.e. proton-pump inhibitor or misoprostol),May exacerbate existing ulcers or cause new/additional ulcers,,SULINDAC,,History of gastric or duodenal ulcers
622,,Avoid unless other alternatives are not effective and patient can take gastroprotective agent (i.e. proton-pump inhibitor or misoprostol),May exacerbate existing ulcers or cause new/additional ulcers,,TOLMETIN,,History of gastric or duodenal ulcers
623,,Avoid,May increase risk of acute kidney injury and further decline of renal function,,ACETYLSALICYLIC ACID,,Chronic Kidney Disease (stage 4 or higher - creatinine clearance <30 mL/min)
624,,Avoid,May increase risk of acute kidney injury and further decline of renal function,,DICLOFENAC,,Chronic Kidney Disease (stage 4 or higher - creatinine clearance <30 mL/min)
625,,Avoid,May increase risk of acute kidney injury and further decline of renal function,,DIFLUNISAL,,Chronic Kidney Disease (stage 4 or higher - creatinine clearance <30 mL/min)
626,,Avoid,May increase risk of acute kidney injury and further decline of renal function,,ETODOLAC,,Chronic Kidney Disease (stage 4 or higher - creatinine clearance <30 mL/min)
627,,Avoid,May increase risk of acute kidney injury and further decline of renal function,,FENOPROFEN,,Chronic Kidney Disease (stage 4 or higher - creatinine clearance <30 mL/min)
628,,Avoid,May increase risk of acute kidney injury and further decline of renal function,,IBUPROFEN,,Chronic Kidney Disease (stage 4 or higher - creatinine clearance <30 mL/min)
629,,Avoid,May increase risk of acute kidney injury and further decline of renal function,,KETOPROFEN,,Chronic Kidney Disease (stage 4 or higher - creatinine clearance <30 mL/min)
630,,Avoid,May increase risk of acute kidney injury and further decline of renal function,,MECLOFENAMIC ACID,,Chronic Kidney Disease (stage 4 or higher - creatinine clearance <30 mL/min)
631,,Avoid,May increase risk of acute kidney injury and further decline of renal function,,MEFENAMIC ACID,,Chronic Kidney Disease (stage 4 or higher - creatinine clearance <30 mL/min)
632,,Avoid,May increase risk of acute kidney injury and further decline of renal function,,MELOXICAM,,Chronic Kidney Disease (stage 4 or higher - creatinine clearance <30 mL/min)
633,,Avoid,May increase risk of acute kidney injury and further decline of renal function,,NABUMETONE,,Chronic Kidney Disease (stage 4 or higher - creatinine clearance <30 mL/min)
634,,Avoid,May increase risk of acute kidney injury and further decline of renal function,,NAPROXEN,,Chronic Kidney Disease (stage 4 or higher - creatinine clearance <30 mL/min)
635,,Avoid,May increase risk of acute kidney injury and further decline of renal function,,OXAPROZIN,,Chronic Kidney Disease (stage 4 or higher - creatinine clearance <30 mL/min)
636,,Avoid,May increase risk of acute kidney injury and further decline of renal function,,PIROXICAM,,Chronic Kidney Disease (stage 4 or higher - creatinine clearance <30 mL/min)
637,,Avoid,May increase risk of acute kidney injury and further decline of renal function,,SULINDAC,,Chronic Kidney Disease (stage 4 or higher - creatinine clearance <30 mL/min)
638,,Avoid,May increase risk of acute kidney injury and further decline of renal function,,TOLMETIN,,Chronic Kidney Disease (stage 4 or higher - creatinine clearance <30 mL/min)
639,,Avoid,May increase risk of acute kidney injury and further decline of renal function,,CELECOXIB,,Chronic Kidney Disease (stage 4 or higher - creatinine clearance <30 mL/min)
640,,Avoid in women (excludes intravaginal estrogen),Lack of efficacy (oral estrogen) and aggravation of incontinence (alpha-1 blockers),,ESTRADIOL,,Urinary incontinence (women)
641,,Avoid in women (excludes intravaginal estrogen),Lack of efficacy (oral estrogen) and aggravation of incontinence (alpha-1 blockers),,ESTRADIOL,,Urinary incontinence (women)
642,,Avoid in women (excludes intravaginal estrogen),Lack of efficacy (oral estrogen) and aggravation of incontinence (alpha-1 blockers),,ESTRADIOL,,Urinary incontinence (women)
643,,Avoid in women (excludes intravaginal estrogen),Lack of efficacy (oral estrogen) and aggravation of incontinence (alpha-1 blockers),,OSPEMIFENE,,Urinary incontinence (women)
644,,Avoid in women (excludes intravaginal estrogen),Lack of efficacy (oral estrogen) and aggravation of incontinence (alpha-1 blockers),,ESTRADIOL,,Urinary incontinence (women)
645,,Avoid in women (excludes intravaginal estrogen),Lack of efficacy (oral estrogen) and aggravation of incontinence (alpha-1 blockers),,CONJUGATED ESTROGENS,,Urinary incontinence (women)
646,,Avoid in women (excludes intravaginal estrogen),Lack of efficacy (oral estrogen) and aggravation of incontinence (alpha-1 blockers),,ESTRONE,,Urinary incontinence (women)
647,,Avoid in women (excludes intravaginal estrogen),Lack of efficacy (oral estrogen) and aggravation of incontinence (alpha-1 blockers),,CONJUGATED ESTROGENS,,Urinary incontinence (women)
648,,Avoid in women (excludes intravaginal estrogen),Lack of efficacy (oral estrogen) and aggravation of incontinence (alpha-1 blockers),,ESTRADIOL,,Urinary incontinence (women)
649,,Avoid in women (excludes intravaginal estrogen),Lack of efficacy (oral estrogen) and aggravation of incontinence (alpha-1 blockers),,DOXAZOSIN,,Urinary incontinence (women)
650,,Avoid in women (excludes intravaginal estrogen),Lack of efficacy (oral estrogen) and aggravation of incontinence (alpha-1 blockers),,PRAZOSIN,,Urinary incontinence (women)
651,,Avoid in women (excludes intravaginal estrogen),Lack of efficacy (oral estrogen) and aggravation of incontinence (alpha-1 blockers),,TERAZOSIN,,Urinary incontinence (women)
652,,Avoid in men unless antimuscarinics are being used for urinary incontinence,May decrease urinary flow and cause urinary retention,,DISOPYRAMIDE,,Benign prostatic hyperplasia (BPH)
653,,Avoid in men unless antimuscarinics are being used for urinary incontinence,May decrease urinary flow and cause urinary retention,,MEPYRAMINE,,Benign prostatic hyperplasia (BPH)
654,,Avoid in men unless antimuscarinics are being used for urinary incontinence,May decrease urinary flow and cause urinary retention,,TRIPROLIDINE,,Benign prostatic hyperplasia (BPH)
655,,Avoid in men unless antimuscarinics are being used for urinary incontinence,May decrease urinary flow and cause urinary retention,,AMITRIPTYLINE,,Benign prostatic hyperplasia (BPH)
656,,Avoid in men unless antimuscarinics are being used for urinary incontinence,May decrease urinary flow and cause urinary retention,,AMOXAPINE,,Benign prostatic hyperplasia (BPH)
657,,Avoid in men unless antimuscarinics are being used for urinary incontinence,May decrease urinary flow and cause urinary retention,,CLOMIPRAMINE,,Benign prostatic hyperplasia (BPH)
658,,Avoid in men unless antimuscarinics are being used for urinary incontinence,May decrease urinary flow and cause urinary retention,,DESIPRAMINE,,Benign prostatic hyperplasia (BPH)
659,,Avoid in men unless antimuscarinics are being used for urinary incontinence,May decrease urinary flow and cause urinary retention,,DOXEPIN,,Benign prostatic hyperplasia (BPH)
660,,Avoid in men unless antimuscarinics are being used for urinary incontinence,May decrease urinary flow and cause urinary retention,,DARIFENACIN,,Benign prostatic hyperplasia (BPH)
661,,Avoid in men unless antimuscarinics are being used for urinary incontinence,May decrease urinary flow and cause urinary retention,,IMIPRAMINE,,Benign prostatic hyperplasia (BPH)
662,,Avoid in men unless antimuscarinics are being used for urinary incontinence,May decrease urinary flow and cause urinary retention,,FESOTERODINE,,Benign prostatic hyperplasia (BPH)
663,,Avoid in men unless antimuscarinics are being used for urinary incontinence,May decrease urinary flow and cause urinary retention,,NORTRIPTYLINE,,Benign prostatic hyperplasia (BPH)
664,,Avoid in men unless antimuscarinics are being used for urinary incontinence,May decrease urinary flow and cause urinary retention,,FLAVOXATE,,Benign prostatic hyperplasia (BPH)
665,,Avoid in men unless antimuscarinics are being used for urinary incontinence,May decrease urinary flow and cause urinary retention,,PAROXETINE,,Benign prostatic hyperplasia (BPH)
666,,Avoid in men unless antimuscarinics are being used for urinary incontinence,May decrease urinary flow and cause urinary retention,,OXYBUTYNIN,,Benign prostatic hyperplasia (BPH)
667,,Avoid in men unless antimuscarinics are being used for urinary incontinence,May decrease urinary flow and cause urinary retention,,PROTRIPTYLINE,,Benign prostatic hyperplasia (BPH)
668,,Avoid in men unless antimuscarinics are being used for urinary incontinence,May decrease urinary flow and cause urinary retention,,SOLIFENACIN,,Benign prostatic hyperplasia (BPH)
669,,Avoid in men unless antimuscarinics are being used for urinary incontinence,May decrease urinary flow and cause urinary retention,,TRIMIPRAMINE,,Benign prostatic hyperplasia (BPH)
670,,Avoid in men unless antimuscarinics are being used for urinary incontinence,May decrease urinary flow and cause urinary retention,,TOLTERODINE,,Benign prostatic hyperplasia (BPH)
671,,Avoid in men unless antimuscarinics are being used for urinary incontinence,May decrease urinary flow and cause urinary retention,,TROSPIUM,,Benign prostatic hyperplasia (BPH)
672,,Avoid in men unless antimuscarinics are being used for urinary incontinence,May decrease urinary flow and cause urinary retention,,PROCHLORPERAZINE,,Benign prostatic hyperplasia (BPH)
673,,Avoid in men unless antimuscarinics are being used for urinary incontinence,May decrease urinary flow and cause urinary retention,,PROMETHAZINE,,Benign prostatic hyperplasia (BPH)
674,,Avoid in men unless antimuscarinics are being used for urinary incontinence,May decrease urinary flow and cause urinary retention,,BENZATROPINE,,Benign prostatic hyperplasia (BPH)
675,,Avoid in men unless antimuscarinics are being used for urinary incontinence,May decrease urinary flow and cause urinary retention,,TRIHEXYPHENIDYL,,Benign prostatic hyperplasia (BPH)
676,,Avoid in men unless antimuscarinics are being used for urinary incontinence,May decrease urinary flow and cause urinary retention,,BROMPHENIRAMINE,,Benign prostatic hyperplasia (BPH)
677,,Avoid in men unless antimuscarinics are being used for urinary incontinence,May decrease urinary flow and cause urinary retention,,CARBINOXAMINE,,Benign prostatic hyperplasia (BPH)
678,,Avoid in men unless antimuscarinics are being used for urinary incontinence,May decrease urinary flow and cause urinary retention,,CHLORPROMAZINE,,Benign prostatic hyperplasia (BPH)
679,,Avoid in men unless antimuscarinics are being used for urinary incontinence,May decrease urinary flow and cause urinary retention,,CHLORPHENIRAMINE,,Benign prostatic hyperplasia (BPH)
680,,Avoid in men unless antimuscarinics are being used for urinary incontinence,May decrease urinary flow and cause urinary retention,,CLOZAPINE,,Benign prostatic hyperplasia (BPH)
681,,Avoid in men unless antimuscarinics are being used for urinary incontinence,May decrease urinary flow and cause urinary retention,,CLEMASTINE,,Benign prostatic hyperplasia (BPH)
682,,Avoid in men unless antimuscarinics are being used for urinary incontinence,May decrease urinary flow and cause urinary retention,,CYPROHEPTADINE,,Benign prostatic hyperplasia (BPH)
683,,Avoid in men unless antimuscarinics are being used for urinary incontinence,May decrease urinary flow and cause urinary retention,,OLANZAPINE,,Benign prostatic hyperplasia (BPH)
684,,Avoid in men unless antimuscarinics are being used for urinary incontinence,May decrease urinary flow and cause urinary retention,,DEXBROMPHENIRAMINE,,Benign prostatic hyperplasia (BPH)
685,,Avoid in men unless antimuscarinics are being used for urinary incontinence,May decrease urinary flow and cause urinary retention,,CHLORPHENIRAMINE,,Benign prostatic hyperplasia (BPH)
686,,Avoid in men unless antimuscarinics are being used for urinary incontinence,May decrease urinary flow and cause urinary retention,,THIORIDAZINE,,Benign prostatic hyperplasia (BPH)
687,,Avoid in men unless antimuscarinics are being used for urinary incontinence,May decrease urinary flow and cause urinary retention,,DIMENHYDRINATE,,Benign prostatic hyperplasia (BPH)
688,,Avoid in men unless antimuscarinics are being used for urinary incontinence,May decrease urinary flow and cause urinary retention,,TRIFLUOPERAZINE,,Benign prostatic hyperplasia (BPH)
689,,Avoid in men unless antimuscarinics are being used for urinary incontinence,May decrease urinary flow and cause urinary retention,,DIPHENHYDRAMINE,,Benign prostatic hyperplasia (BPH)
690,,Avoid in men unless antimuscarinics are being used for urinary incontinence,May decrease urinary flow and cause urinary retention,,DOXYLAMINE,,Benign prostatic hyperplasia (BPH)
691,,Avoid in men unless antimuscarinics are being used for urinary incontinence,May decrease urinary flow and cause urinary retention,,HYDROXYZINE,,Benign prostatic hyperplasia (BPH)
692,,Avoid in men unless antimuscarinics are being used for urinary incontinence,May decrease urinary flow and cause urinary retention,,ATROPINE,,Benign prostatic hyperplasia (BPH)
693,,Avoid in men unless antimuscarinics are being used for urinary incontinence,May decrease urinary flow and cause urinary retention,,MECLIZINE,,Benign prostatic hyperplasia (BPH)
694,,Avoid in men unless antimuscarinics are being used for urinary incontinence,May decrease urinary flow and cause urinary retention,,,,Benign prostatic hyperplasia (BPH)
695,,Avoid in men unless antimuscarinics are being used for urinary incontinence,May decrease urinary flow and cause urinary retention,,,,Benign prostatic hyperplasia (BPH)
696,,Avoid in men unless antimuscarinics are being used for urinary incontinence,May decrease urinary flow and cause urinary retention,,METHYLSCOPOLAMINE,,Benign prostatic hyperplasia (BPH)
697,,Avoid in men unless antimuscarinics are being used for urinary incontinence,May decrease urinary flow and cause urinary retention,,DICYCLOMINE,,Benign prostatic hyperplasia (BPH)
698,,Avoid in men unless antimuscarinics are being used for urinary incontinence,May decrease urinary flow and cause urinary retention,,HOMATROPINE METHYLBROMIDE,,Benign prostatic hyperplasia (BPH)
699,,Avoid in men unless antimuscarinics are being used for urinary incontinence,May decrease urinary flow and cause urinary retention,,HYOSCYAMINE,,Benign prostatic hyperplasia (BPH)
700,,Avoid in men unless antimuscarinics are being used for urinary incontinence,May decrease urinary flow and cause urinary retention,,CYCLOBENZAPRINE,,Benign prostatic hyperplasia (BPH)
701,,Avoid in men unless antimuscarinics are being used for urinary incontinence,May decrease urinary flow and cause urinary retention,,METHYLSCOPOLAMINE,,Benign prostatic hyperplasia (BPH)
702,,Avoid in men unless antimuscarinics are being used for urinary incontinence,May decrease urinary flow and cause urinary retention,,ORPHENADRINE,,Benign prostatic hyperplasia (BPH)
703,,Avoid in men unless antimuscarinics are being used for urinary incontinence,May decrease urinary flow and cause urinary retention,,PROPANTHELINE,,Benign prostatic hyperplasia (BPH)
